RVL Pharmaceuticals (RVLPQ) 10-K 20 Mar 23 2022 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Mar. 17, 2023	Jun. 30, 2022
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2022
Current Fiscal Year End Date	--12-31
Entity File Number	001-38709
Entity Registrant Name	RVL Pharmaceuticals plc
Entity Incorporation, State or Country Code	L2
Entity Tax Identification Number	00-0000000
Entity Address, Address Line One	400 Crossing Boulevard
Entity Address, City or Town	Bridgewater
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	08807
City Area Code	908
Local Phone Number	809-1300
Title of 12(b) Security	Ordinary shares, $0.01 nominal value per share
Trading Symbol	RVLP
Security Exchange Name	NASDAQ
ICFR Auditor Attestation Flag	false
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		99,349,814
Entity Public Float			$ 44.9
Auditor Name	Ernst & Young LLP
Auditor Firm ID	42
Auditor Location	Iselin, New Jersey
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Entity Central Index Key	0001739426
Amendment Flag	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 44,543	$ 40,444
Accounts receivable and other receivables	3,031	2,133
Inventories, net	784	838
Prepaid expenses and other current assets	8,617	12,901
Financial commitment asset		3,063
Total current assets	56,975	59,379
Property, plant and equipment, net	1,276	866
Operating lease assets	512	1,368
Indefinite-lived intangible assets	13,900	27,210
Goodwill	55,847	55,847
Total assets	128,510	144,670
Current liabilities:
Trade accounts payable	2,407	3,777
Accrued liabilities	15,395	13,077
Current portion of debt	1,432	2,409
Current portion of obligations under finance leases	10	5
Current portion of lease liability	435	839
Income taxes payable - current portion	44	1
Total current liabilities	19,723	20,108
Long-term debt (measured at fair value and representing $75,000 and $55,000 of aggregate unpaid principal at December 31, 2022 and December 31, 2021, respectively)	55,500	43,800
Warrant liability	1,951	3,220
Long-term portion of obligations under finance leases	18
Long-term portion of lease liability	94	592
Income taxes payable - long term portion	70	66
Deferred taxes	61	151
Total liabilities	77,417	67,937
Commitments and contingencies (see Note 16)
Shareholders' equity:
Ordinary shares ($0.01 nominal value, 400,000,000 shares authorized, 99,161,375 and 83,297,567 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively)	992	833
Preferred shares ($0.01 nominal value, 40,000,000 shares authorized, no shares issued and outstanding)	0	0
Euro deferred shares (€1.00 nominal value, 25,000 shares authorized, no shares issued and outstanding)	0	0
Additional paid in capital	619,323	591,730
Accumulated deficit	(569,222)	(517,530)
Accumulated other comprehensive income		1,700
Total shareholders' equity	51,093	76,733
Total liabilities and shareholders' equity	$ 128,510	$ 144,670

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) $ in Thousands	Dec. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2022 € / shares	Dec. 31, 2021 USD ($) $ / shares shares	Dec. 31, 2021 € / shares
Consolidated Balance Sheets
Aggregate unpaid principal balance | $	$ 75,000		$ 55,000
Ordinary shares, nominal value (in dollars per share) | $ / shares	$ 0.01		$ 0.01
Ordinary shares, number of shares authorized	400,000,000		400,000,000
Ordinary shares, number of shares issued	99,161,375		83,297,567
Ordinary shares, number of shares outstanding	99,161,375		83,297,567
Preferred shares, nominal value (in dollars per share) | $ / shares	$ 0.01		$ 0.01
Preferred shares, number of shares authorized	40,000,000		40,000,000
Preferred shares, number of shares issued	0		0
Preferred shares, number of shares outstanding	0		0
Euro deferred shares, nominal value (in euros per share) | € / shares		€ 1		€ 1
Euro deferred shares, number of shares authorized	25,000		25,000
Euro deferred shares, number of shares issued	0		0
Euro deferred shares, number of shares outstanding	0		0

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Total revenues	$ 49,721	$ 17,501
Cost of goods sold	9,456	3,618
Gross profit	40,265	13,883
Selling, general and administrative expenses	81,979	87,463
Research and development expenses	3,966	6,930
Impairment of intangible assets	13,310	7,880
Total operating expenses	99,255	102,273
Operating loss before gain on sales of product rights, net	(58,990)	(88,390)
Gain on sales of product rights, net		5,636
Operating loss	(58,990)	(82,754)
Interest expense and amortization of debt discount	3,110	3,036
Change in fair value of debt and interest expense	(2,857)	982
Change in fair value of warrants	(1,269)	(5,571)
Other non-operating (income) expense, net	(6,262)	1,333
Total other non-operating income	(7,278)	(220)
Loss before income taxes	(51,712)	(82,534)
Income tax (benefit) expense, continuing operations	(20)	315
Loss from continuing operations	(51,692)	(82,849)
Gain on sales of discontinued operations		4,062
Income from discontinued operations before income taxes		13,570
Income tax benefit, discontinued operations		297
Income from discontinued operations, net of tax		17,929
Net loss	(51,692)	(64,920)
Reclassification adjustment of cumulative foreign currency translation losses, net of tax		2,229
Change in fair value of debt due to change in credit risk, net of tax	(1,700)	1,700
Other comprehensive (loss) income	(1,700)	3,929
Comprehensive loss	$ (53,392)	$ (60,991)
(Loss) earnings per ordinary share:
(Loss) earnings per ordinary share, Continuing operations, basic	$ (0.58)	$ (1.23)
(Loss) earnings per ordinary share, Continuing operations, diluted	(0.58)	(1.23)
(Loss) earnings per ordinary share, Discontinued operations, basic		0.27
(Loss) earnings per ordinary share, Discontinued operations, diluted	0	0.27
(Loss) earnings per ordinary share, basic	(0.58)	(0.96)
(Loss) earnings per ordinary share, diluted	$ (0.58)	$ (0.96)
Weighted average ordinary shares outstanding:
Weighted average ordinary shares outstanding, basic	89,797,357	67,354,336
Weighted average ordinary shares outstanding, diluted	89,797,357	67,354,336
Net product sales
Total revenues	$ 34,221	$ 7,511
Royalty and licensing revenue
Total revenues	$ 15,500	$ 9,990

Consolidated Statements of Chan

Consolidated Statements of Changes in Shareholders' Equity - USD ($) $ in Thousands	Ordinary shares	Additional Paid-in Capital [Member]	Accumulated deficit	Accumulated other comprehensive income (loss)	Total
Stockholders' equity, beginning balance at Dec. 31, 2020	$ 625	$ 548,070	$ (452,610)	$ (2,229)	$ 93,856
Shares, Outstanding, Beginning Balance at Dec. 31, 2020	62,545,832
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share compensation	$ 5	7,818			7,823
Share compensation, shares	456,741
Net loss			(64,920)		(64,920)
Payments for taxes related to the net share settlement of equity awards		(783)			(783)
Proceeds from issuance of ordinary shares, net of offering costs	$ 203	36,625			36,828
Proceeds from issuance of ordinary shares, net of offering costs (Shares)	20,294,994
Reclassification adjustment of cumulative foreign currency translation losses, net of tax				2,229	2,229
Change in fair value of debt due to change in credit risk, net of tax				1,700	1,700
Stockholders' equity, ending balance at Dec. 31, 2021	$ 833	591,730	(517,530)	1,700	76,733
Shares, Outstanding, Ending Balance at Dec. 31, 2021	83,297,567
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share compensation, value	$ 4	4,257			4,261
Share compensation, shares	412,196
Net loss			(51,692)		(51,692)
Payments for taxes related to the net share settlement of equity awards		(143)			(143)
Proceeds from issuance of ordinary shares, net of offering costs	$ 155	23,479			23,634
Proceeds from issuance of ordinary shares, net of offering costs (Shares)	15,451,612
Change in fair value of debt due to change in credit risk, net of tax				$ (1,700)	(1,700)
Stockholders' equity, ending balance at Dec. 31, 2022	$ 992	$ 619,323	$ (569,222)		$ 51,093
Shares, Outstanding, Ending Balance at Dec. 31, 2022	99,161,375

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash Flows from Operating Activities:
Net loss from continuing operations	$ (51,692)	$ (82,849)
Net income from discontinued operations		17,929
Net loss	(51,692)	(64,920)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	375	8,175
Share compensation	4,070	7,594
Reclassification adjustment of cumulative foreign currency translation losses to earnings		2,229
Change in fair value of debt	(10,000)	(318)
Change in fair value of warrants	(1,269)	(5,571)
Impairment of intangible assets	13,310	7,880
Deferred income tax expense (benefit)	(90)	(194)
(Gain) loss on sale of fixed and leased assets	(878)	1,180
Gain on sales of product rights, net		(5,636)
Gain on sales of discontinued operations		(4,062)
Amortization of deferred financing and loan origination fees	3,063	1,606
Write off of deferred financing and loan origination fees		1,462
Financing fees recognized in earnings associated with debt	914	3,306
Change in operating assets and liabilities:
Accounts receivable and other receivables	(898)	7,108
Inventories, net	54	2,595
Prepaid expenses and other current and non-current assets	4,283	(6,198)
Trade accounts payable	(1,370)	(134)
Accrued and other current liabilities	2,318	(10,834)
Net cash used in operating activities	(37,810)	(54,732)
Cash Flows from Investing Activities:
Proceeds from product rights disposal		7,300
Proceeds from discontinued operations		110,845
Proceeds from sale of fixed and leased assets	878	90
Purchases of property, plant and equipment	(752)	(1,782)
Net cash provided by investing activities	126	116,453
Cash Flows from Financing Activities:
Payments on finance lease obligations	(9)	(37)
Proceeds from insurance financing loan	1,724	3,317
Payments on insurance financing loan	(2,700)	(909)
Payments for taxes related to net share settlement of share-based awards	(143)	(783)
Proceeds from issuance of debt, net of issuance costs	19,086	51,795
Proceeds from issuance of ordinary shares, net of issuance costs	23,634	32,414
Proceeds from issuance of ordinary shares under ESPP	191	233
Debt repayments		(221,360)
Net cash provided by (used in) financing activities	41,783	(135,330)
Net change in cash and cash equivalents	4,099	(73,609)
Cash and cash equivalents, beginning of period	40,444	114,053
Cash and cash equivalents, end of period	$ 44,543	$ 40,444

Organization and Nature of Oper

Organization and Nature of Operations	12 Months Ended
	Dec. 31, 2022
Organization and Nature of Operations
Organization and Nature of Operations	Note 1. Organization and Nature of Operations RVL Pharmaceuticals plc, an Irish public limited company, together with its subsidiaries (collectively, the “Company”), is a specialty pharmaceutical company focused on the development and commercialization of products that target markets with underserved patient populations in the ocular medicine and medical aesthetics therapeutic areas. ​ In July 2020, the Company received regulatory approval from the FDA for RVL-1201, or Upneeq, (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or droopy or low-lying eyelids, in adults. Upneeq was commercially launched in September 2020 to a limited number of eye care professionals with commercialization operations expanded in 2021 among ophthalmology, optometry and oculoplastic specialties. In February 2022, Upneeq was commercially expanded into the medical aesthetics market in the United States. ​ The Company’s commercial operations are conducted by its wholly-owned subsidiaries, RVL Pharmaceuticals, Inc. (“RVL Pharmaceuticals”) and RVL Pharmacy, LLC (“RVL Pharmacy”). RVL Pharmacy conducts pharmacy operations dedicated to the processing and fulfillment of prescriptions for Upneeq. ​ Unless otherwise indicated or required by the context, references throughout to the “Company,” refer to the Company’s continuing operations following the sale of its Legacy Business (see Note 4). ​

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2022
Basis of Presentation and Summary of Significant Accounting Policies
Basis of Presentation and Summary of Significant Accounting Policies	Note 2. Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation Basis of Presentation Principles of Consolidation Discontinued Operations Summary of Significant Accounting Policies Use of Estimates Foreign Currency Translation Our subsidiary in Argentina had operated in a highly inflationary environment, as a result, we had previously recognized cumulative foreign currency translation losses in accumulated other comprehensive income (loss) in accordance with U.S. GAAP. During the year ended December 31, 2021, the Company curtailed its operations in Argentina and, upon the related liquidation becoming substantially complete, reclassified all accumulated foreign currency translation losses to selling, general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss. Cash and Cash Equivalents Accounts Receivable and Allowance for Credit Losses —Accounts receivable result primarily from sales of pharmaceutical products and from amounts due under revenue sharing, license and royalty arrangements. Other receivables result primarily from payroll retention credits and other miscellaneous activities. The Company is exposed to credit losses primarily through sales of its products. Accounts receivable are recorded at amortized cost less an allowance for expected credit losses that are not expected to be recovered. The Company’s expected loss methodology for accounts receivable is developed using historical collection experience, a review of the current status of a customer’s trade receivables, and current and future market conditions. Due to the short-term nature of such accounts receivables, the estimated portion thereof that may not be collected is based on the aging of accounts receivable balances and the financial condition of customers. The Company’s monitoring activities include timely account reconciliations, dispute resolution, payment confirmation, consideration of customers’ financial condition and macroeconomic conditions. Balances are written-off when determined to be uncollectible. Except for the allowance for credit losses, which is reflected as part of selling, general and administrative expenses, the provisions for all other customer reserves are reflected as a reduction of revenues in the consolidated statements of operations and comprehensive loss. The Company considered the current and expected future economic and market conditions surrounding a novel strain of the coronavirus, referred to as COVID-19, and determined that its estimate of credit losses was not significantly impacted. Fair Value of Financial Instruments Fair Value Measurement The valuation hierarchy is composed of three levels. The classification within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The levels within the valuation hierarchy are described below: Level 1 — Assets and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs, such as quoted prices in active markets for identical assets or liabilities. Level 2 — Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals. Level 3 — Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities. Inventories Property, Plant and Equipment ​ ​ ​ ​ Asset category Depreciable life Leasehold improvements Lesser of the useful life of the improvement or the terms of the underlying lease Machinery 3 - 15 years Furniture, fixtures and equipment 3 - 10 years Computer hardware and software 3 - 12 years ​ Goodwill and Indefinite Lived Intangible Assets st In-Process Research and Development (“IPR&D”) intangible assets represent the value assigned to incomplete Research & Development (“R&D”) projects that principally represent rights to develop and sell a product that the Company has acquired through business combinations or developed internally which, at that time, have not reached technological feasibility. These assets are not amortized but are subject to impairment testing until regulatory approval is obtained and the product is launched, subject to certain specified conditions and management judgment, or abandonment of a project. At the time of any transfer from an IPR&D asset to an amortizing asset an impairment evaluation is performed. The useful life of any resultant amortizing asset is generally determined by identifying the period in which substantially all of the cash flows are expected to be generated. Such assets will be amortized over their respective estimated useful lives. Impairment testing of IPR&D assets requires the development of significant estimates and assumptions involving the determination of estimated net cash flows for each year for each project or product (including net revenues, cost of sales, research and development expenses, selling and marketing costs and other costs which may be allocated), the appropriate discount rate to select in order to measure the risk inherent in each future cash flow stream, the assessment of each asset’s life cycle, the potential regulatory and commercial success risks, and competitive trends impacting each asset and related cash flow stream as well as other factors. The major risks and uncertainties associated with the timely and successful completion of the IPR&D projects include legal risk, market risk and regulatory risk. If applicable, upon abandonment of the IPR&D project, the assets are reduced to zero. IPR&D assets are assessed for impairment on an annual basis as of October 1 st Impairment charges resulting from annual or interim goodwill and indefinite-lived intangible asset impairment assessments, if any, are classified within total operating expenses, in the accompanying consolidated statements of operations and comprehensive loss. Product Sales Revenue Recognition, Revenue is recorded at the transaction price, which is the amount of consideration the Company expects to receive in exchange for transferring products to a customer. The Company determines the transaction price based on fixed consideration. The amount of revenue we recognize is equal to the selling price, adjusted for any variable consideration, which included discounts and allowances at the time revenues were recognized. In determining the transaction price, a significant financing component does not exist since the customer typically pays for the product in advance of the transfer of the product or shortly thereafter. Royalty Revenue Licensing Revenue Freight Business Combinations Business Combinations Goodwill represents the excess purchase price over the fair value of the tangible net assets and intangible assets acquired in a business combination. Acquisition-related expenses are recognized separately from business combinations and are expensed as incurred. If the business combination provides for contingent consideration, the Company records the contingent consideration at fair value at the acquisition date. Changes in fair value of contingent consideration resulting from events after the acquisition date, such as earn-outs, are recognized as follows: 1) if the contingent consideration is classified as equity, the contingent consideration is not re-measured and its subsequent settlement is accounted for within equity, or 2) if the contingent consideration is classified as a liability, the changes in fair value are recognized in earnings. Purchases of developed products and licenses that are accounted for as an asset acquisition are capitalized as intangible assets and amortized over an estimated useful life. IPR&D assets acquired as part of an asset acquisition are expensed immediately if they have no alternative future uses. Research and Development Costs Advertising Share-based Compensation Stock Compensation Share compensation expense is measured at the date of grant, based on the fair value of an award and recognized ratably over its vesting term, which is generally the vesting period on a graded vesting basis. Share compensation expense for awards with vesting conditions other than service are recognized at the time that those conditions will be achieved. Forfeitures of unvested awards are recognized as they occur by reversing any expense previously recorded in the period of forfeiture. The Company typically issues new ordinary shares upon exercise or vesting of awards. The grant date fair value of restricted stock units is based on the market price of ordinary shares as of the grant date. The grant date fair value of stock options and performance stock units is measured using a Black-Scholes Merton option-pricing model and a Monte Carlo simulation model, respectively, using assumptions based on the terms of each award, the expected behavior of grant recipients and peer company data. Expected volatility is calculated based on a weighting of our own stock price volatility and/or the historical stock price trends of similar entities within our industry over a period of time commensurate with the expected term. The risk-free interest rate is based on U.S. Treasury observed market rates continuously compounded over the duration of the expected term. The expected term of stock options is estimated as the midpoint of the weighted average vesting period and the contractual term. The Company accounts for purchases made under its employee share purchase plan using the estimate grant date fair value in accordance with ASC 718. A purchase price discount and look-back feature under the plan cause it to be compensatory and the Company to recognize share compensation expense on a straight-line basis over the requisite service period. The Company values related shares using a Black-Scholes Merton option-pricing model. When share-based compensation arrangements are modified, the modification is treated as an exchange of the original award for a new award with immediate expense recognition for any incremental value. The incremental value, if any, is measured as the excess of the fair value of new award over the fair value of the original award, each based on circumstances and assumptions as of the modification date. Leasing the underlying asset becomes available for use. The Company has elected to account for non-lease components associated with leases and lease components as a single lease component. The Company recognizes a right-of use asset, which represents the Company’s right to use the underlying asset for the lease term, and a lease liability, which represents the present value of the Company’s obligation to make payments arising over the lease term. The present value of the lease payments are calculated using either the implicit interest rate in the lease or an incremental borrowing rate. ​ Income Taxes The Company recognizes the benefit of an uncertain tax position that it has taken or expects to take on income tax returns it files if such tax position is more likely than not to be sustained on examination by the taxing authorities, based on the technical merits of the position. These tax benefits are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate resolution. Comprehensive Income or Loss Basic and Diluted Earnings or Loss Per Share In periods of cumulative retained earnings, if ever, as a result of the holders of warrants being entitled to dividends (see Note 20), the warrants are participating securities and will be included in the computation of basic and diluted earnings or loss per share following the two-class method. Segment Reporting ​ Supplemental Cash Flow Disclosures ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ ​ 2022 2021 Cash paid for: ​ ​ ​ ​ ​ ​ Interest ​ $ 4,890 ​ $ 8,518 Income taxes ​ $ 184 ​ $ 2,361 Non-cash financing activities: ​ ​ ​ ​ ​ ​ Allocation of equity offering proceeds to warrant liability (see Note 20) ​ $ — ​ $ 8,791 Allocation of debt offering proceeds to ordinary shares (see Note 20) ​ $ — ​ $ 9,243 Recognition of financial commitment asset from ordinary share issuance (see Notes 12 & 20) ​ $ — ​ $ 3,361 ​ The Company received $3.1 million in tax refunds during the year ended December 31, 2022 related to income taxes paid in prior periods. Recently Adopted Accounting Standards In December 2019, the FASB issued Accounting Standards Update No. 2019-12, Income Taxes Topic 740, Simplifying the Accounting for Income Taxes (“ASU 2019-12”). The Company adopted ASU 2019-12 as required effective January 1, 2021. Among other updates to the accounting for income taxes, ASU 2019-12 removed the exception to the incremental approach for intra-period tax allocation when there is a loss from continuing operations and income or a gain from other items. Accordingly, the Company’s loss from continuing operations for the year ended December 31, 2021 does not reflect a tax benefit amounting to $3.2 million that would have been recognized if ASU 2019-12 was not adopted. Recently Issued Accounting Standards In August 2020, the FASB issued Accounting Standards Update 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity ​ There are no other recently issued accounting standards that are expected to have a material impact to the Company’s financial position or results of operations upon adoption.

Liquidity

Liquidity	12 Months Ended
	Dec. 31, 2022
Liquidity
Liquidity	Note 3. Liquidity At December 31, 2022, the Company had cash and cash equivalents of $44.5 million, an accumulated deficit of $569.2 million, and total long-term debt with aggregate principal maturities of $75.0 million, with such maturities commencing in March 2024 and extending through October 2026 (see Note 12). In addition, the Company’s primary indebtedness contains various restrictive covenants including minimum liquidity and minimum quarterly product sales requirements. For the years ended December 31, 2022 and 2021, the Company incurred losses from continuing operations of $51.7 million and $82.8 million, respectively, and used $37.8 million and $54.7 million, respectively, in cash from operating activities. The divestiture of the Legacy Business in 2021 resulted in the loss of substantially all the Company’s revenue generating assets (see Note 4). The Company’s current business plan is focused on the continued commercialization and growth of Upneeq, which has and will continue to diminish the Company’s cash flows in at least the near term. The Company will require additional capital to fund its operating needs, including the expanded commercialization of Upneeq and other activities. The Company expects to incur significant expenditures and sustain operating losses in the future. Management of the Company does not believe that current sources of liquidity will be sufficient to fund the Company’s planned expenditures and meet its obligations, including the minimum liquidity covenant, for at least 12 months following the date the accompanying consolidated financial statements are issued without raising additional funding. As a result, there is a substantial doubt as to the Company’s ability to operate as a going concern. The Company’s ability to continue as a going concern will require it to obtain additional funding, generate positive cash flow from operations and/or enter into strategic alliances or sell assets. Management’s plans to address these conditions include pursuing one or more of the following options to secure additional funding, none of which can be guaranteed or is entirely within its control, (i) raise funds through additional sales of ordinary shares, through equity sales agreements with brokers/dealers or other public or private equity financings, (ii) raise funds through borrowings under new and/or existing debt facilities and/or convertible debt, and/or (iii) raise non-dilutive funds through product collaborations and/or to partner or sell a portion or all rights to any of the Company’s assets. There can be no assurance that the Company will receive cash proceeds from any of these potential sources or, to the extent cash proceeds are received, such proceeds would be sufficient to support its current operating plan for at least the next 12 months from the date the accompanying consolidated financial statements are issued. The sale of additional equity or convertible debt securities may result in dilution to the Company’s shareholders. If the Company raises additional funds through the issuance of debt securities or preferred shares, these securities could provide for rights senior to those of its ordinary shares and could contain covenants that would further restrict its operations. Additional funds may not be available when the Company needs them, on terms that are acceptable to it, or at all. The accompanying consolidated financial statements have been prepared on a going concern basis, which assumes the realization of assets and settlement of liabilities in the normal course of business, and therefore do not include any adjustments to the amount and classification of assets and liabilities that may be necessary should the Company be unable to continue as a going concern.

Discontinued Operations

Discontinued Operations	12 Months Ended
	Dec. 31, 2022
Discontinued Operations
Discontinued Operations	Note 4. Discontinued Operations On August 27, 2021, the Company announced the closing of the divestiture of its legacy portfolio of branded and non-promoted products and its Marietta, Georgia manufacturing facility (collectively, the “Legacy Business”) to certain affiliates of Alora Pharmaceuticals LLC (“Alora”) for $111 million in cash upon closing, subject to certain adjustments, and up to $60 million in additional contingent milestone payments. Pursuant to the divestiture, the Company retained the rights to Upneeq and to arbaclofen extended release (“ER”) tablets which is under development for the treatment of spasticity in multiple sclerosis. For the year ended December 31, 2022, the Company received an aggregate of $5.0 million in cash from Alora related to contingent milestone payments earned in connection with the sale of the Legacy Business, with such income being recognized and classified within other non-operating income or expense, net in the accompanying consolidated statements of operations and comprehensive loss. The Company determined that the divestiture of the Legacy Business represented a strategic shift that would have a major effect on its business and therefore met the criteria for classification as discontinued operations. Accordingly, the Legacy Business is reported as discontinued operations in accordance with ASC 205-20, Discontinued Operations ​ The following table presents the results of discontinued operations (in thousands): ​ ​ ​ ​ ​ ​ ​ Year Ended ​ ​ ​ December 31, 2021 ​ Total revenues ​ $ 62,395 ​ Cost of goods sold (inclusive of depreciation and amortization) ​ 30,018 ​ Selling, general and administrative expenses ​ 5,468 ​ Research and development expenses ​ ​ 5,882 ​ Income from operations ​ 21,027 ​ Interest expense and amortization of debt discount ​ 6,399 ​ Other non-operating expense, net ​ 1,058 ​ Income from discontinued operations before gain on disposal and provision for income taxes ​ 13,570 ​ Income tax benefit ​ ​ 297 ​ Income from discontinued operations before gain on disposal ​ ​ 13,867 ​ Gain on sales of discontinued operations ​ ​ 4,062 ​ Income from discontinued operations, net of tax ​ $ 17,929 ​ ​ As a result of the legal requirement to repay certain existing indebtedness upon the disposition of the Legacy Business, the Company allocated interest expense (inclusive of amortization of debt discount) on such debt to the discontinued operations for periods prior to the disposal based on the ratio of repaid debt to total debt. ​ The following table presents the significant non-cash items and purchases of property, plant and equipment for the discontinued operations that are included in the accompanying consolidated statements of cash flows (in thousands): ​ ​ ​ ​ ​ ​ Year Ended Cash flows from operating activities: ​ December 31, 2021 Depreciation and amortization ​ $ 6,583 Share compensation ​ ​ 619 ​ ​ ​ ​ Cash flows from investing activities: ​ ​ ​ Purchases of property, plant and equipment ​ $ (1,335) ​

Revenues

Revenues	12 Months Ended
	Dec. 31, 2022
Revenues
Revenues	​ Note 5. Revenues The Company’s performance obligations are to provide its pharmaceutical products based upon purchase orders from customers. The performance obligations are satisfied at a point in time, typically upon delivery, when the customer obtains control of the pharmaceutical product. Predominately, the Company collects payment in advance from its customers. From time to time, the Company may invoice a customer after the products have been delivered in which case payments are typically due within 30 days. The following table presents disaggregated revenues from contracts with customers (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ ​ 2022 2021 Net product sales - Upneeq ​ $ 34,221 ​ $ 7,511 ​ Royalty and licensing revenue ​ 15,500 ​ ​ 9,990 ​ Total revenues ​ $ 49,721 ​ $ 17,501 ​ ​ On July 28, 2020, RVL Pharmaceuticals entered into a License Agreement with Santen Pharmaceutical Co. Ltd (“Santen”), granting Santen exclusive development, registration, and commercialization rights to RVL-1201 in Japan, China, and other Asian countries as well as Europe, the Middle East and Africa (“EMEA”) countries (the “License Agreement”). Under the License Agreement, RVL Pharmaceuticals is entitled to certain development and regulatory milestone payments. RVL Pharmaceuticals is also entitled to royalty payments on net sales of RVL-1201 in Santen commercialization territories. On March 29, 2022, RVL Pharmaceuticals entered into the First Amendment to License Agreement (the “Amendment”) with Santen, amending the License Agreement. Under the terms of the Amendment, effective March 31, 2022, RVL Pharmaceuticals became entitled to receive an upfront cash payment of $15.5 million, and the remaining developmental and regulatory cash milestone payments, were removed. Pursuant to the terms of the Amendment, new developmental and regulatory cash milestone payments with an aggregate value of up to $1.0 million will be payable to RVL Pharmaceuticals if achieved. In addition, the territories were expanded to include additional EMEA countries and Canada, and during the first five years following the effective date of the Amendment, Santen was granted an option to expand the territories to include Russia, subject to additional upfront and milestone payments of $2.0 million and $1.0 million, respectively. Further, under the terms of the Amendment, if RVL Pharmaceuticals desires to enter into an agreement to license certain rights related to the License Agreement to a third party in Russia, then Santen will have a right to exercise an option to expand the territories to include Russia or to match the terms of the agreement with the third party. During the years ended December 31, 2022 and 2021, the Company recognized $15.5 million and $10.0 million, respectively, in license revenue from Santen under the Amendment and the License Agreement, respectively, as all performance obligations were met. A contract liability is recorded as deferred revenue on the consolidated balance sheets when customers are billed in advance of performance obligations being satisfied, and revenue is recognized upon satisfaction of all performance obligations. The amount of revenue recognized during the years ended December 31, 2022 and 2021 that was included in the opening deferred balance of the same fiscal year was less than million for both reporting periods. During the year ended December 31, 2022, the Company’s deferred revenue balance increased as a result of higher sales volumes and from an increase in consideration received for performance obligations yet to be satisfied at December 31, 2022. At December 31, 2022, all deferred revenue was expected to become recognized as revenues within one year and is included within accrued expenses, a component of current liabilities, in the accompanying consolidated balance sheets (see Note 10). Contract assets primarily relate to rights to consideration for goods or services transferred to the customer when the right is conditional on something other than the passage of time. Contract assets are transferred to accounts receivable when the rights become unconditional. The Company had no contract assets at December 31, 2022 and 2021. ​ The following table presents the various adjustments recognized against gross product sales (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 2021 Gross product sales ​ $ 35,588 ​ $ 7,997 Less provisions for: ​ ​ ​ ​ ​ Chargebacks ​ (11) ​ ​ (2) Discounts and allowances ​ (1,356) ​ ​ (484) Net product sales ​ $ 34,221 ​ $ 7,511 ​

Accounts Receivable, Other Rece

Accounts Receivable, Other Receivables, Sales Deductions and Allowances	12 Months Ended
	Dec. 31, 2022
Accounts Receivable, Other Receivables, Sales Deductions and Allowances
Accounts Receivable, Other Receivables, Sales Deductions and Allowances	Note 6. Accounts Receivable, Other Receivables, Discounts and Allowances Accounts receivable result primarily from sales of pharmaceutical products and from amounts due under revenue sharing, license and royalty arrangements. Other receivables result primarily from payroll retention credits and other miscellaneous activities. ​ The following table presents the components of accounts receivable and other receivables (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ December 31, December 31, ​ ​ 2022 ​ 2021 Trade accounts receivable ​ $ 947 ​ $ — Other receivables ​ 2,084 ​ 2,133 Total accounts receivable and other receivables ​ $ 3,031 ​ $ 2,133 ​ The following table presents the periodic activity within various reserves recognized against gross accounts receivable (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Discounts ​ ​ ​ ​ ​ ​ ​ Commercial ​ and ​ ​ ​ ​ ​ Chargebacks ​ Rebates ​ Allowances ​ Total Balance at January 1, 2021 ​ $ — ​ $ 4 ​ $ 1 ​ $ 5 Provision ​ ​ 2 ​ ​ — ​ ​ 484 ​ ​ 486 Charges processed ​ ​ (2) ​ ​ (4) ​ ​ (485) ​ ​ (491) Balance at December 31, 2021 ​ ​ — ​ ​ — ​ ​ — ​ ​ — Provision ​ ​ 11 ​ ​ — ​ ​ 1,356 ​ ​ 1,367 Charges processed ​ ​ (11) ​ ​ — ​ ​ (1,356) ​ ​ (1,367) Balance at December 31, 2022 ​ $ — ​ $ — ​ $ — ​ $ — ​ ​

Inventories

Inventories	12 Months Ended
	Dec. 31, 2022
Inventories
Inventories	Note 7. Inventories At December 31, 2022 and 2021, the Company had finished goods inventory of $0.8 million and $0.8 million, respectively. The Company maintains an allowance for excess and obsolete inventory, as well as inventory where its cost is in excess of its net realizable value. The following table presents activity in the allowance for excess and obsolete inventory (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ ​ ​ 2022 ​ ​ 2021 Balance at beginning of period ​ $ 34 ​ $ — Provision ​ (1) ​ 34 Charges processed ​ (31) ​ — Balance at end of period ​ $ 2 ​ $ 34 ​

Property, Plant and Equipment,

Property, Plant and Equipment, Net	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment, Net
Property, Plant and Equipment, Net	Note 8. Property, Plant and Equipment, Net The following table presents the components of property, plant and equipment (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ ​ 2022 2021 Leasehold improvements ​ $ 386 ​ $ 1,129 Machinery ​ ​ 17 ​ ​ — Furniture, fixtures and equipment ​ ​ — ​ ​ 4 Computer hardware and software ​ ​ 1,324 ​ ​ 1,302 ​ ​ 1,727 ​ 2,435 Accumulated depreciation ​ ​ (1,151) ​ ​ (1,641) ​ ​ ​ 576 ​ ​ 794 Construction in progress ​ ​ 700 ​ ​ 72 ​ ​ $ 1,276 ​ $ 866 ​ Depreciation expense was $0.4 million and $1.5 million for the years ended December 31, 2022 and 2021, respectively.

Goodwill and Indefinite-Lived I

Goodwill and Indefinite-Lived Intangible Assets	12 Months Ended
	Dec. 31, 2022
Goodwill and Indefinite-Lived Intangible Assets
Goodwill and Indefinite-lived Intangible Assets	Note 9. Goodwill and Indefinite-Lived Intangible Assets Goodwill Goodwill is presented net of accumulated impairment charges of $47.8 million at December 31, 2022 and 2021. The following table sets forth the changes in the carrying value of goodwill (in thousands): ​ ​ ​ ​ ​ ​ Goodwill January 1, 2021 ​ $ 55,847 Impairments ​ ​ — December 31, 2021 ​ ​ 55,847 Impairments ​ ​ — December 31, 2022 ​ $ 55,847 ​ In conjunction with the sale of the Legacy Business, the Company evaluated goodwill for impairment and determined that there were no indications that the fair value of goodwill was less than its carrying value. As of October 1, 2022, the Company performed a qualitative assessment for goodwill and concluded there were no indications that the fair value of goodwill was less than its carrying value. Indefinite-Lived Intangible Assets Subsequent to the divestiture of the Legacy Business in 2021 (see Note 4), the Company retained the rights to arbaclofen ER tablets which is under development for the alleviation of signs and symptoms of spasticity resulting from multiple sclerosis for which the Company has completed Phase III clinical trials and for which the Company is exploring opportunities to divest, out-license or otherwise partner with a third party to monetize its net investment (see Note 3). ​ At December 31, 2022 and 2021, the Company held indefinite-lived intangible assets for the right to develop and sell arbaclofen ER that had a gross recognized carrying value of $64.0 million at each date, aggregate impairment losses of $50.1 million and $36.8 million, respectively, and a net carrying amount of $13.9 million and $27.2 million, respectively. ​ Based on the results of a quantitative impairment assessment performed in conjunction with the announcement of the sale of the Legacy Business relative to arbaclofen ER, the Company recognized an impairment charge of $7.9 million during the year ended December 31, 2021, related to a delay in anticipated commercialization of the product candidate, if approved. During the fourth quarter of 2022, the Company, having received a potentially adverse response letter from the U.S. Food and Drug Administration (“FDA”) subsequent to an October 10, 2022 filing of a new Special Protocol Assessment, performed a quantitative IPR&D impairment assessment and conclude that the IPR&D asset was impaired. Accordingly, the Company recognized an impairment charge of $13.3 million during the year ended December 31, 2022, related to a further delay and potentially increased costs in anticipated commercialization of the product candidate, if approved. ​ A quantitative impairment test for indefinite-lived intangible assets, when performed, is determined using a discounted cash flow model that necessitates the development of estimated net cash flows for each asset, the appropriate discount rate to select for each future cash flow stream, the assessment of each asset’s life cycle, the potential regulatory and commercial success risks, and competitive trends impacting each asset and related cash flow stream as well as other factors. IPR&D assets are also subject to adjustments reducing their anticipated revenues and costs by a probability of success, or POS, factor based upon empirical research of probabilities a new drug candidate would be approved based on the candidate’s stage of clinical development. ​ A variety of the above-referenced valuation assumptions are based on significant inputs not observable in the market and thus the Company’s quantitative impairment tests, when performed, represent Level 3 measurements within the fair value hierarchy. The POS factor applied during the IPR&D quantitative impairment assessments was 69.6% and the discount rates applied were 17.5% and 12.5%, during the years ended December 31, 2022 and 2021, respectively. The Company believes the estimated net cash flows, POS factor, discount rates and other inputs and assumptions are consistent with those that a market participant would use.

Accrued Liabilities

Accrued Liabilities	12 Months Ended
	Dec. 31, 2022
Accrued Liabilities
Accrued Liabilities	Note 10. Accrued Liabilities The following table presents the components of accrued liabilities (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ December 31, December 31, ​ ​ 2022 ​ 2021 Accrued expenses and other liabilities ​ $ 5,894 ​ $ 7,897 Accrued compensation ​ ​ 3,908 ​ ​ 4,504 Accrued interest ​ ​ 2,300 ​ ​ — Accrued royalties ​ 1,144 ​ 200 Deferred revenue ​ 1,923 ​ 67 Accrued research and development ​ ​ 226 ​ ​ 409 Total accrued liabilities ​ $ 15,395 ​ $ 13,077 ​

Leases

Leases	12 Months Ended
	Dec. 31, 2022
Leases
Leases	Note 11. Leases The Company leases office space in Bridgewater, New Jersey for its principal office and leases office and warehouse space in Sayreville, New Jersey for its pharmacy operations both under a non-cancelable lease that expires in November 2023. The Company also leases certain vehicles under operating leases. At December 31, 2022, the Company’s operating leases had remaining lease terms ranging from 0.9 years to 1.5 years. The following table presents lease assets and liabilities and identifies their classification in the accompanying consolidated balance sheets (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, Leases Classification ​ 2022 ​ 2021 Assets ​ ​ ​ ​ ​ ​ ​ Operating Operating lease assets ​ $ 512 ​ $ 1,368 Finance Property, plant and equipment, net ​ ​ 28 ​ ​ 5 Total leased assets ​ ​ $ 540 ​ $ 1,373 ​ ​ ​ ​ ​ ​ ​ ​ Liabilities ​ ​ ​ ​ ​ ​ ​ Current ​ ​ ​ ​ ​ ​ ​ Operating Current portion of lease liability ​ $ 435 ​ $ 839 Finance Current portion of obligations under finance leases ​ ​ 10 ​ ​ 5 ​ ​ ​ ​ ​ ​ ​ ​ Non-current ​ ​ ​ ​ ​ ​ ​ Operating Long-term portion of lease liability ​ ​ 94 ​ ​ 592 Finance Long-term portion of obligations under finance leases ​ ​ 18 ​ ​ — Total lease liabilities ​ ​ $ 557 ​ $ 1,436 ​ The Company recognizes lease expense on a straight-line basis over the lease term. The following table presents the various components of lease cost and identifies their classification in the accompanying consolidated statements of operations and comprehensive loss (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, Lease Cost Classification ​ 2022 ​ 2021 Operating lease cost Selling, general and administrative expenses ​ $ 1,111 ​ $ 1,425 ​ Research and development expenses ​ ​ — ​ ​ 28 ​ Cost of goods sold ​ ​ 42 ​ ​ 41 ​ ​ ​ ​ ​ ​ ​ ​ Finance lease cost ​ ​ ​ ​ ​ ​ ​ Amortization of leased assets Cost of goods sold ​ ​ 10 ​ ​ 24 Interest on lease liabilities Interest expense and amortization of debt discount ​ ​ — ​ ​ — Total lease cost ​ ​ $ 1,163 ​ $ 1,518 ​ The table below presents the future minimum rental payments, exclusive of taxes, insurance and other costs, under operating leases (in thousands): ​ ​ ​ ​ ​ Year Ending December 31, Operating Leases 2023 ​ $ 445 2024 ​ 93 Total lease payments ​ ​ 538 Less: interest ​ ​ 9 Present value of lease payments ​ $ 529 ​ At December 31, 2022, there is an insignificant amount of future minimum lease payments required under finance leases. The following tables presents the weighted-average remaining lease term and the weighted-average discount rate of our leases (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ Lease Term and Discount Rate ​ 2022 ​ 2021 ​ Weighted average remaining lease term (years) ​ ​ ​ ​ ​ ​ ​ Operating leases ​ ​ 1.2 ​ ​ 1.8 ​ Finance leases ​ ​ 2.5 ​ ​ 0.6 ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average discount rate ​ ​ ​ ​ ​ ​ ​ Operating leases ​ ​ 3.56 % ​ 4.15 % Finance leases ​ ​ 10.50 % ​ 2.06 % ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ Other Information ​ 2022 ​ 2021 ​ Cash paid for amounts included in the measurement of lease liabilities: ​ ​ ​ ​ ​ ​ ​ Operating cash flows for operating leases ​ $ (1,153) ​ $ (1,478) ​ Operating cash flows for finance leases ​ ​ (2) ​ ​ — ​ Financing cash flows for finance leases ​ ​ (10) ​ ​ (16) ​ ​ For the years ended December 31, 2022 and 2021, the Company recorded less than $0.1 million and $0.7 million, respectively, of leased assets obtained in exchange for new operating lease liabilities and an insignificant amount of leased assets obtained in exchange for new finance lease liabilities in each period. During the years ended December 31, 2022 and 2021, the Company disposed of less than $0.1 million of leased assets in each period.

Financing Arrangements

Financing Arrangements	12 Months Ended
	Dec. 31, 2022
Financing Arrangements
Financing Arrangements	Note 12. Financing Arrangements The following table presents the components of long-term debt and financing obligations (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ December 31, ​ ​ 2022 ​ 2021 Senior Secured Notes (measured at fair value) ​ $ 55,500 ​ $ 43,800 Note payable — insurance financing ​ 1,432 ​ 2,409 Total debt and financing obligations ​ 56,932 ​ 46,209 Less: current portion of debt ​ (1,432) ​ (2,409) Long-term debt ​ $ 55,500 ​ $ 43,800 ​ The following table presents the aggregation of principal maturities of long-term debt and financing obligations (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ending December 31, Debt Obligations 2023 ​ $ 1,432 2024 ​ 15,000 2025 ​ ​ 15,000 2026 ​ ​ 45,000 Total future minimum payments ​ ​ 76,432 Less: current portion of debt principal ​ ​ (1,432) Non-current portion of debt principal ​ $ 75,000 ​ ​ Senior Secured Notes ​ On October 1, 2021, the Company entered into a note purchase agreement (the “Note Purchase Agreement”) with, among others, Athyrium Opportunities IV Acquisition LP (the “Administrative Agent”) and Athyrium Opportunities IV Acquisition 2 LP, as a purchaser, providing for the issuance of senior secured notes in three separate tranches (the “Senior Secured Notes”). On October 12, 2021, the Company issued $55.0 million first tranche Senior Secured Notes, a portion of the proceeds of which, together with the proceeds from a concurrent underwritten equity offering (see Note 20), were used to repay in full the Prior Term Loans (defined below). Prior to October 12, 2022, upon satisfaction of certain conditions, including a minimum net product sales target for Upneeq over a specified period of time, the Company could request second tranche Senior Secured Notes of up to $20.0 million. Additionally, prior to October 12, 2023, the Company could request third tranche Senior Secured Notes of up to $25.0 million, in the sole discretion of the purchaser. On August 4, 2022, the Company entered into a first amendment to the Note Purchase Agreement (the “First Amendment”) with, among others, Athyrium Opportunities IV Co-Invest 1 LP (the “New Purchaser”), certain other purchasers party thereto (together with the New Purchaser, the “Purchasers”) and the Administrative Agent, which amended the Note Purchase Agreement (as amended, the “Amended Note Purchase Agreement”). ​ The First Amendment provided, among other things, for the issuance of $20.0 million of secured second tranche Senior Secured Notes, dated as of August 8, 2022. Furthermore, under the First Amendment, the Purchasers committed to purchase certain third tranche Senior Secured Notes in an aggregate principal amount of up to $25.0 million at any time prior to April 15, 2023, upon the satisfaction of certain conditions, including a minimum net product sales target for Upneeq over a specified period of time. ​ Further, the First Amendment provided for the replacement of a LIBOR-based interest rate under the Note Purchase Agreement with a Term SOFR-based interest rate. After September 30, 2022, the Senior Secured Notes bear interest at an annual rate of 9.0% plus adjusted three-month term SOFR, with a floor of 1.50% and a cap of 3.00%, payable in cash quarterly in arrears. At December 31, 2022, the interest rate applicable to the aggregate outstanding Senior Secured Notes is 12.0%. ​ The Senior Secured Notes require quarterly repayments equal to 5.0% of the principal outstanding beginning on March 31, 2024 with any residual balance due at maturity on October 12, 2026. The Senior Secured Notes may be voluntarily prepaid upon the satisfaction of certain conditions and with each such prepayment being accompanied by, as applicable, (i) a make-whole premium, (ii) an exit fee of 2.0% of the principal amount of the Senior Secured Notes prepaid, (iii) certain other fees, indemnities and expenses, and (iv) all accrued interest on the Senior Secured Notes being so prepaid. The First Amendment provided for the reset of the date from which the make-whole premium is applicable with respect to the first tranche Senior Secured Notes. Specifically, the make-whole premium start date with respect to the first tranche Senior Secured Notes changed from October 12, 2021, to either (A) March 1, 2022, if the third tranche Senior Secured Notes are not issued or (B) August 8, 2022, if the third tranche Senior Secured Notes are issued. The Senior Secured Notes must be prepaid upon the receipt of cash under certain defined conditions, including from voluntary and involuntary asset dispositions, extraordinary receipts, issuance of new indebtedness, and contingent milestone payments for the Legacy Business paid by Alora, each such prepayment being accompanied by, as applicable, the fees described in (i) through (iv) above. The exit fee described in (ii) above is payable on the principal amount of all notes prepaid or repaid, including upon the repayment of the notes upon maturity. The Senior Secured Notes are guaranteed on a senior secured basis by the Company and certain of its subsidiaries. The Senior Secured Notes and guarantees are secured by substantially all of the assets of the Company and its U.S. subsidiaries. Subject to certain exceptions and qualifications, the Amended Note Purchase Agreement contains covenants that, among other things, limit the Company’s ability and the ability of its restricted subsidiaries, including the guarantors, to (i) incur additional indebtedness or issue certain disqualified capital stock, (ii) create liens, (iii) transfer or sell assets, (iv) make certain investments, loans, advances and acquisitions, (v) engage in consolidations, amalgamations or mergers, or sell, transfer or otherwise dispose of all or substantially all of their assets, and (vi) enter into certain transactions with affiliates. The Amended Note Purchase Agreement also provides for customary events of default. In addition, the restrictive covenants in the Amended Note Purchase Agreement require the Company to comply with certain minimum liquidity requirements and minimum quarterly product sales requirements. Under the terms of the Amended Note Purchase Agreement, the Company is required to maintain unrestricted cash and cash equivalents greater than or equal to $15.0 million (with a decrease to $12.5 million, if the third tranche Senior Secured Notes have been issued and the Consolidated Upneeq Net Product Sales (as defined in the Note Purchase Agreement) are greater than or equal to $55.0 million), and, as of the end of each fiscal quarter, it is required to maintain consolidated Upneeq net product sales greater than or equal to specified quarterly thresholds (currently at $7.0 million for the fiscal quarter ending March 31, 2023, and increasing in $1.0 million increments each quarter thereafter until the quarter ending June 30, 2024, for which quarter and all subsequent quarters the threshold is $12.0 million). At December 31, 2022, the Company was in compliance with all covenants under the Amended Note Purchase Agreement. ​ During the year ended December 31, 2021, the Company incurred aggregate debt issuance costs of $2.1 million related to the Senior Secured Notes, $1.5 million and $0.6 million of which were recognized as financial commitment assets underlying the first and second tranche Senior Secured Notes, respectively. ​ The Company elected the fair value option of accounting on the first tranche Senior Secured Notes upon issuance and, accordingly, a proportionate amount of related debt issuance costs of $1.5 million were immediately written off to selling, general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss. The Company’s residual financial commitment asset related to the undrawn second tranche Senior Secured Notes, was being amortized over the relevant one-year commitment period, however, upon the issuance of the second tranche Senior Secured Notes in August 2022 the residual financial commitment asset was immediately expensed. As of December 31, 2021, the second tranche financial commitment asset had a carrying value of $3.1 million and was recorded within current assets in the accompanying consolidated balance sheet. During the year ended December 31, 2022, the Company recognized $3.1 million of amortization expense from the second tranche Senior Secured Notes financial commitment asset with such expense being recorded within interest expense and amortization of debt discount in the accompanying consolidated statements of operations and comprehensive loss. ​ The Company also elected the fair value option of accounting on the second tranche Senior Secured Notes upon issuance and, accordingly, $0.9 million of related debt issuance costs were immediately written off in August 2022, with such expense being recorded within selling, general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss. ​ On a recurring basis, changes in fair value of Senior Secured Notes will be presented in the accompanying consolidated statements of operations and comprehensive loss at each reporting period (see Note 21). ​ In the year ended December 31, 2022, the Company obtained waivers from the applicable purchasers of mandatory repayments of an aggregate of $5.0 million in principal of the Senior Secured Notes as otherwise required under the Note Purchase Agreement, in exchange for a consent fee of $0.2 million, resulting in net retained proceeds of $4.8 million. ​ Prior Credit Agreement Prior to October 12, 2021, the Company was party to a Credit Agreement, dated February 3, 2016, and as amended from time-to-time, under which an aggregate principal amount of $327.5 million of secured term loans were previously issued (the “Prior Term Loans”) and that provided for revolving credit commitments up to $50.0 million (the “Prior Revolving Facility,” and together with the Prior Term Loans, the “Prior Credit Agreement”). During the six months ended June 30, 2021, pursuant to the terms of the Prior Credit Agreement, the Company exercised its right to cure a shortfall in certain financial covenants which resulted in the mandatory prepayment of $5.3 million against the Prior Term Loans. On June 25, 2021, the Company amended the Prior Credit Agreement (the “Fifth Amendment”), pursuant to which liens on the Legacy Business were released and the parties agreed to (i) reduce the outstanding Prior Term Loans balance to $30.0 million upon the closing of the divestiture of the Legacy Business, (ii) terminate the Prior Revolving Facility (50% upon signing of the Fifth Amendment and the remaining 50% upon closing of the Legacy Business divestiture), and (iii) shorten the maturity of any remaining term loans to November 21, 2021. On August 27, 2021, the Company announced the closing of the divestiture of the Legacy Business (see Note 4). Proceeds from the divestiture of the Legacy Business, together with cash on hand were used to repay $186.1 million of debt under the Prior Term Loans and the Prior Revolving Facility expired without ever having been drawn upon. On October 12, 2021, using a portion of the proceeds from the issuance of Senior Secured Notes, together with the proceeds from a concurrent equity offering (see Note 20), the Company repaid the final $30.0 million outstanding principal under the Prior Term Loans. As a result of the complete principal repayments under the Prior Term Loans during the year ended December 31, 2021, the Company incurred immaterial fees and expenses upon extinguishment and also wrote off an aggregate of $1.5 million in debt issuance costs with the related expense classified within other non-operating gain or loss in the consolidated statements of operations and comprehensive loss.

Concentrations and Credit Risk

Concentrations and Credit Risk	12 Months Ended
	Dec. 31, 2022
Concentrations and Credit Risk
Concentrations and Credit Risk	Note 13. Concentrations and Credit Risk For the year ended December 31, 2022, the Company has a significant concentration of credit risk with one customer representing 94% of trade accounts receivable. Purchasing The Company has an exclusive supply agreement with a third party for the manufacturing and delivery of Upneeq. Sales by Product & Geography For the years ended December 31, 2022 and 2021, Upneeq sales in the United States accounted for 100% of the Company's total gross product sales.

Share-Based Compensation

Share-Based Compensation	12 Months Ended
	Dec. 31, 2022
Share-Based Compensation.
Share-Based Compensation	Note 14. Share-Based Compensation Overview of Plans Our outstanding share-based compensation awards have been issued under a succession of plans sponsored by various companies within our consolidation group, including, (i) the Amended and Restated 2018 Incentive Plan, which first became effective upon the Company’s initial public offering on October 22, 2018 (the "2018 Plan"), (ii) the Amended and Restated 2016 Equity Incentive Plan, which first became effective in February 2016 (the “2016 Plan”) and (iii) the 2018 Employee Share Purchase Plan, which became effective in September 2019 upon adoption and approval by the Company’s Board of Directors (the “ESP Plan”). 2016 Plan 2018 Plan ESP Plan worth of ordinary shares, valued at the start of the purchase period, under the ESP Plan in any calendar year. There is no minimum holding period associated with shares purchased pursuant to this plan. An employee’s purchase rights terminate immediately upon termination of employment. Share-based Compensation The compensation cost, that has been charged against income for all incentive plans, excluding the ESP Plan, was $3.9 million for the year ended December 31, 2022 and $6.8 million for the year ended December 31, 2021. Share-Based Award Activity The following tables of share-based award activity are based on the historical activity of the continuing and discontinued operations of the Company on a combined basis. A summary of stock option activity under the 2016 Plan as of December 31, 2022 and 2021, and changes during the years then ended is presented below: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2016 Plan - Share Options ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ Weighted ​ ​ Average ​ ​ ​ Number of ​ Average ​ ​ Remaining ​ ​ Share Options Exercise Price ​ ​ Contractual Term Outstanding at January 1, 2021 ​ ​ 2,827,100 ​ $ 14.95 ​ ​ ​ Granted ​ ​ — ​ ​ — ​ ​ ​ Exercised ​ ​ — ​ ​ — ​ ​ ​ Expired / Forfeited ​ ​ (312,690) ​ $ 14.95 ​ ​ ​ Outstanding at December 31, 2021 ​ ​ 2,514,410 ​ $ 14.95 ​ ​ ​ Vested at December 31, 2021 ​ ​ 2,514,410 $ 14.95 ​ ​ ​ Granted ​ ​ — ​ ​ — ​ ​ ​ Exercised ​ ​ — ​ ​ — ​ ​ ​ Expired / Forfeited ​ ​ (239,874) ​ $ 14.95 ​ ​ ​ Outstanding at December 31, 2022 ​ ​ 2,274,536 ​ $ 14.95 ​ ​ 3.4 years Vested at December 31, 2022 ​ ​ 2,274,536 $ 14.95 ​ ​ 3.4 years ​ The aggregate intrinsic value of options outstanding under the 2016 Plan at December 31, 2022 was $0 . The fair value of options vested under the 2016 Plan during the year ended December 31, 2021 was immaterial. ​ A summary of option activity under the 2018 Plan as of December 31, 2022 and 2021, and changes during the year then ended is presented below: ​ ​ ​ ​ ​ ​ ​ ​ ​ 2018 Plan - Share Options ​ ​ ​ Weighted ​ Weighted ​ ​ ​ ​ Average ​ Average Remaining ​ ​ Number of ​ Exercise ​ Contractual ​ Share Options Price Term Outstanding at January 1, 2021 96,400 ​ $ 7.00 ​ Granted ​ 3,174,886 ​ ​ 1.80 ​ ​ Exercised ​ — ​ ​ — ​ ​ Expired / Forfeited ​ (88,850) ​ $ 5.98 ​ ​ Outstanding at December 31, 2021 ​ 3,182,436 ​ $ 1.84 ​ ​ Vested Options at December 31, 2021 ​ — ​ ​ ​ ​ ​ Granted ​ 114,700 ​ $ 1.24 ​ ​ Exercised ​ — ​ ​ — ​ ​ Expired / Forfeited ​ (796,914) ​ $ 1.82 ​ ​ Outstanding at December 31, 2022 ​ 2,500,222 ​ $ 1.82 ​ 8.8 years Vested Options at December 31, 2022 ​ 659,119 ​ $ 1.94 ​ 8.8 years ​ The aggregate intrinsic value of options outstanding under the 2018 Plan at December 31, 2022 was $0 . The weighted average grant date fair value for the options granted during the years ended December 31, 2022 and 2021 was , respectively. The fair value of options vested under the 2018 Plan during the years ended December 31, 2022 and 2021 were both . The fair value of option awards is estimated using the Black-Scholes option-pricing model. Exercise price of each award is generally not less than the per share fair value in effect as of that award date. The determination of fair value using the Black-Scholes model is affected by the Company’s share fair value as well as assumptions regarding a number of complex and subjective variables, including expected price volatility, risk-free interest rate and projected employee share option exercise behaviors. ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended ​ Year Ended ​ ​ ​ December 31, ​ December 31, ​ ​ 2022 2021 Expected volatility 84 % 81 % Risk-free interest rate 1.63 - 3.78 % 1.25% - 1.29 % Expected dividend yield — % — % Expected life of options in years 6.25 ​ 6.08 - 6.25 ​ ​ The estimated fair value of the options is expensed over the requisite service period, which is generally the vesting period on a graded vesting basis. As of December 31, 2022 there was years. For all periods prior to the IPO, our Board of Directors has determined the fair value of the common unit underlying our option with assistance from management and based upon information available at the time of grant. Prior to our IPO, given the absence of a public trading market for our common units, estimating the fair value of our common units was based on the actual operational and financial performance, current business conditions and discounted cash flow projections. The estimated fair value of our common units, prior to our IPO was adjusted for lack of marketability and control existing at the grant date. ​ Restricted and Performance Stock Units On May 18, 2020 and May 20, 2020, the Company granted performance stock units (“PSUs”) under the 2018 Plan to certain key employees of the Company that gives holders the potential to receive a certain number of earned PSUs at the end of a pre-determined term. Unless earlier terminated, forfeited, relinquished or expired, the earned PSUs will vest in full on the vesting date, subject to the grantee remaining in continuous employment from the date of grant through the vesting date. The vesting date is the third anniversary from the grant date for the PSUs granted on May 18, 2020 and the fifth anniversary from the grant date for the PSUs granted on May 20, 2020. The number of PSUs that become earned PSUs as of the end of the performance period shall be equal to the number of PSUs multiplied by the applicable percentage based on Stock Price Hurdle attainment, as set forth in the PSU Award Agreement and 2018 Plan. A summary of PSU activity under the 2018 Plan as of December 31, 2021, and changes during the year then ended is presented below: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2018 Plan - PSUs ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted- ​ ​ Weighted- ​ ​ ​ Number of ​ ​ Average Grant ​ ​ Average Remaining ​ ​ ​ PSUs ​ ​ Date Fair Value ​ ​ Term (Years) Outstanding at January 1, 2021 ​ ​ 789,799 ​ $ 4.99 ​ ​ ​ PSUs granted ​ ​ — ​ ​ — ​ ​ ​ PSUs vested ​ ​ — ​ ​ — ​ ​ ​ PSUs forfeited ​ ​ (789,799) ​ ​ 4.99 ​ ​ ​ Outstanding at December 31, 2021 ​ ​ — ​ $ — ​ ​ — ​ Closing of the Legacy Business divestiture triggered acceleration of vesting of the PSUs, however the PSUs were automatically forfeited due to market conditions not being met in accordance with the 2018 Plan. A summary of RSU activity under the 2018 Plan as of December 31, 2022 and 2021, and changes during the years then ended is presented below: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2018 Plan - RSUs ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted- ​ ​ Weighted- ​ ​ ​ Number of ​ ​ Average Grant ​ ​ Average Remaining ​ ​ ​ RSUs ​ ​ Date Fair Value ​ ​ Contractual Term Outstanding at January 1, 2021 ​ ​ 1,991,557 ​ $ 5.99 ​ ​ ​ RSUs granted ​ ​ 161,188 ​ ​ 3.25 ​ ​ ​ RSUs vested ​ ​ (601,306) ​ ​ 6.05 ​ ​ ​ RSUs forfeited ​ ​ (199,164) ​ ​ 4.73 ​ ​ ​ Outstanding at December 31, 2021 ​ ​ 1,352,275 ​ $ 5.82 ​ ​ ​ RSUs granted ​ ​ 75,000 ​ ​ 1.88 ​ ​ ​ RSUs vested ​ ​ (310,783) ​ ​ 5.76 ​ ​ ​ RSUs forfeited ​ ​ (82,843) ​ ​ 5.18 ​ ​ ​ Outstanding at December 31, 2022 ​ ​ 1,033,649 ​ $ 5.60 ​ ​ 1.5 years ​ During the years ended December 31, 2022 and 2021 we granted RSUs covering an equal number of our ordinary shares to employees and certain directors with a weighted average grant date fair value of $1.88 and $3.25, respectively. The fair value of RSUs are determined on the date of grant based on the market price of our ordinary shares as of that date. The fair value of the RSUs is recognized ratably over the vesting period of four years for employees and one years. ESP Plan The Company accounts for employee stock purchases made under its ESP Plan using the estimate grant date fair value in accordance with ASC 718. The purchase price discount and the look-back feature cause the ESP Plan to be compensatory and the Company to recognize compensation expense. Share compensation expense is recognized on a straight-line basis over the requisite service period. The Company recognized $167,731 and $134,077 of share compensation expense from the ESP Plan for the years ended December 31, 2022 and 2021, respectively. The Company values ESP Plan shares using the Black-Scholes model. As of December 31, 2022 there were no unrecognized share compensation expense related to the ESP Plan. There were 207,903 and 76,432 ordinary shares issued under the ESP Plan during the years ended December 31, 2022 and 2021, respectively. On January 5, 2023, the Company issued 96,612 ordinary shares to the employees who participated in the ESP Plan during the offering period ended December 31, 2022.

Earnings or Loss Per Ordinary S

Earnings or Loss Per Ordinary Share	12 Months Ended
	Dec. 31, 2022
Earnings or Loss Per Ordinary Share
Earnings or Loss Per Ordinary Share	Note 15. Earnings or Loss Per Ordinary Share The following potentially dilutive securities have been excluded from the weighted average ordinary shares outstanding in the computation of diluted earnings or loss per share because the impact of including them would have been anti-dilutive: ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 2021 Performance and restricted stock units ​ 1,033,649 ​ 1,352,275 Share options to purchase ordinary shares ​ 4,774,758 ​ 5,696,846 Warrants to purchase ordinary shares ​ 16,100,000 ​ 16,100,000 Ordinary shares to be purchased through employee stock purchase plan ​ 96,612 ​ 129,258 ​

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies
Commitments and Contingencies	Note 16. Commitments and Contingencies Contingent Milestone Payments Upon closing of the Legacy Business divestiture, the only strategic business agreements remaining with the Company are contingent payment obligations related to the acquisition of Upneeq and its related intellectual property, including contingent earn out obligations pursuant to the acquisition of RevitaLid, Inc., the original owner of Upneeq. The aggregate amount of future contingent payments due under the strategic business agreements, based on defined regulatory milestone events and milestones based on levels of US and ex-US net product sales of Upneeq, was $0.8 million in the aggregate at December 31, 2022. ​ The aggregate expense associated with contingent payments related to the acquisitions of Upneeq and Revitalid in the years ended December 31, 2022 and 2021 was $2.8 million and $0.5 million, respectively, with such amounts classified within cost of goods sold in the accompanying consolidated statements of operations and comprehensive loss. ​ Royalty Obligations The Company does not have agreements with third parties that require the Company to make minimum royalty payments. Supply Agreement Obligations The only supply agreement remaining with the Company after the divestiture of the Legacy Business is that related to the supply of Upneeq, which contains no minimum purchase obligations. The Company has no enforceable and legally binding purchase obligations at December 31, 2022. Defined Contribution Plan The Company maintains a 401(k) plan that covers eligible employees subject to certain age and length of service requirements. The 401(k) plan provides for employer matching contributions equal to 100% of each employee's elective deferrals up to 3% of base salary, plus 50% of each employee's elective deferrals between 3% and 5% of base salary. For the years ended December 31, 2022 and 2021, the Company recognized expenses related to its contributions under the Plan of $0.7 million and $0.7 million, respectively. Legal Proceedings The Company is a party in legal proceedings and potential claims arising from time to time in the ordinary course of its business. The amount, if any, of ultimate liability with respect to such matters cannot be determined. Despite the inherent uncertainties of litigation, management of the Company believes that the ultimate disposition of such proceedings and exposures will not have a material adverse impact on the financial condition, results of operations, or cash flows of the Company. On February 16, 2018, the Company received FDA approval for its amantadine extended release tablets under the trade name Osmolex ER. On that same date the Company filed in the Federal District Court for the District of Delaware a Complaint for Declaratory Judgment of Noninfringement of certain patents owned by Adamas Pharmaceuticals, Inc. (Osmotica Pharmaceutical US LLC and Vertical Pharmaceuticals, LLC vs. Adamas Pharmaceuticals, Inc. and Adamas Pharma, LLC). Adamas was served with the Complaint on February 21, 2018. Adamas filed an answer on April 13, 2018 denying the allegations in the Complaint and reserving the ability to raise counterclaims as the litigation progresses. On September 20, 2018, Adamas filed an amended answer to the Company’s Complaint for Declaratory Judgment of Noninfringement, with counterclaims alleging infringement of certain patents included in the Company’s Complaint and requesting that the court grant Adamas damages, injunctive relief and attorneys’ fees. On December 2, 2020, we entered into an agreement to settle the litigation with Adamas. Under the terms of the agreement, both parties agreed to drop their respective claims relating to the patent litigation, and Adamas agreed to acquire the global rights to Osmolex ER from the Company for $7.5 million. The sale of the global rights to Osmolex ER closed in January 2021 at which time the related gain of $5.6 million was recorded in the consolidated statements of operations and comprehensive loss under gain on sale of product rights, net. Additionally, in connection with the settlement and the sale of the global rights to Osmolex ER, the parties entered into a supply agreement pursuant to which the Company agreed to supply Adamas with amantadine extended release tablets for a six-year term, subject to possible two-year extensions and customary closing conditions. On April 30, 2019, the Company was served with a complaint in an action entitled Leo Shumacher, et al., v. Osmotica Pharmaceuticals plc, et al., Superior Court of New Jersey, Somerset County No. SOM-L-000540-19 Jeffrey Tello, et al., v. Osmotica Pharmaceuticals plc, et al., Superior Court of New Jersey, Somerset County No. SOM-L-000617-19 actions, reiterating the previously pled allegations and adding an additional individual defendant. The parties participated in a mediation and reached an agreement in principle to settle the litigation on December 15, 2020. The parties subsequently negotiated a settlement agreement setting forth the terms of the settlement. On May 18, 2021, plaintiffs filed an unopposed motion for preliminary approval of the settlement and notice to the proposed settlement class, which motion was granted by the court on June 11, 2021. The settlement, which was finally approved by the Court on November 10, 2021, calls for a payment by the Company of million (a portion of which was covered by applicable insurance) and fully resolves all claims asserted in the litigation against all defendants named in the litigation, including the Company. No party admitted any wrongdoing as part of the settlement, which was reached to avoid the further cost and distraction of litigation. ​ On April 19, 2021, we were served with a complaint in an action entitled United States ex rel. Lupinetti, et al. v. Exeltis USA, Inc., et al., Northern District of Illinois, No. 1:19-cv-00825 . The complaint named us and

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2022
Income Taxes
Income Taxes	Note 17. Income Taxes RVL Pharmaceuticals plc is an Irish public limited company. Since the majority of the Company’s operations is in the U.S., the statutory income tax rate that is applicable is the U.S. federal income tax rate of 21%. On August 27, 2021, and in connection with the divestiture of the Legacy Business, the Company sold its interest in certain subsidiaries which resulted in a federal capital loss. The following table shows the components of loss before income taxes and the related current and deferred income taxes from continuing operations (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ December 31, ​ ​ 2022 ​ 2021 Loss before income taxes ​ ​ U.S. operations ​ $ (48,197) ​ $ (68,975) Non-U.S. operations ​ (3,515) ​ (13,559) Total loss before income taxes ​ (51,712) ​ (82,534) Current income tax expense (benefit) ​ ​ Federal ​ 86 ​ 192 State ​ 105 ​ (41) Foreign ​ (68) ​ 20 Total current income tax expense (benefit) ​ 123 ​ 171 Deferred income tax expense (benefit) ​ ​ Federal ​ (90) ​ 149 Foreign ​ (53) ​ (5) Total deferred income tax expense (benefit) ​ (143) ​ 144 Total income tax expense (benefit) ​ $ (20) ​ $ 315 ​ The following table provides a reconciliation of the U.S. statutory federal income tax rate to the Company's effective income tax rate from continuing operations: ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ December 31, ​ ​ 2022 ​ 2021 U.S. federal income tax at 21% statutory rate 21.00 % 21.00 % State and local income taxes, net of federal benefit 6.28 % 2.65 % Differences in tax effects on foreign income 0.23 % 8.81 % Federal tax credits 0.95 % 0.29 % Uncertain tax positions (0.01) % — % NOL carryback rate differential ​ — % (0.03) % Tax audit adjustments ​ 0.11 % 0.01 % Change in valuation allowance (23.24) % (33.83) % Permanent adjustments (0.63) % (0.01) % Return to provision ​ (4.65) % — % Other — % 0.73 % Effective income tax rate 0.04 % (0.38) % ​ Deferred income taxes reflect the tax effects of the differences between the amounts recorded as assets and liabilities for financial statement purposes and the comparable amounts recorded for income tax purposes. The following table depicts the significant components of deferred tax assets (liabilities) (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ December 31, ​ ​ 2022 ​ 2021 Deferred tax assets: ​ ​ Accrued expenses ​ $ 714 ​ $ 827 Inventories ​ 4 ​ — Net operating losses ​ 26,944 ​ ​ 21,134 Capital losses ​ ​ 23,805 ​ ​ 23,845 Right of use liabilities ​ 120 ​ 340 Tax credits ​ ​ 8,207 ​ ​ 7,232 Debt costs ​ ​ 3,311 ​ ​ 4,740 Interest expense ​ ​ 4,367 ​ ​ 2,168 Share compensation ​ ​ 709 ​ ​ 285 Other ​ 3,561 ​ 2,916 Less: valuation allowance ​ (64,872) ​ (52,853) Deferred tax liabilities: ​ ​ ​ ​ Property plant & equipment ​ (28) ​ — Intangible assets ​ ​ (2,339) ​ ​ (6,353) Debt costs ​ ​ (4,447) ​ ​ (4,107) Right of use assets ​ (117) ​ (325) Total deferred income taxes ​ $ (61) ​ $ (151) ​ At December 31, 2022, the Company had federal net operating loss carryforwards of $70.2 million, state net operating loss carryforwards of $139.2 million, net operating loss carryforwards in certain foreign tax jurisdictions of $109.9 million, which will begin to expire in 2026 and total tax credit carryforwards of $8.6 million, primarily consisting of Federal Orphan Drug Tax Credits that are expected to be fully realized prior to their expiration, beginning in 2036. The Company also had federal capital loss carryforwards of $95.8 million at December 31, 2022, which will expire in 2026. The Company assesses the realizability of the deferred tax assets at each balance sheet date based on actual and forecasted operating results in order to determine the proper amount, if any, required for a valuation allowance. The Company maintains valuation allowances on deferred tax assets applicable to entities in the U.S. and foreign jurisdictions for which separate income tax returns are filed, where realization of the related deferred tax assets from future profitable operations is not reasonably assured. During the years ended December 31, 2022 and 2021, the valuation allowance increased by $12.0 million and $25.1 million, respectively. Should applicable deferred tax assets ultimately become realizable, such resulting reduction in the valuation allowance would generally be recognized as an income tax benefit. The Company files income tax returns in U.S. federal, state and certain international jurisdictions. For U.S. federal and certain state income tax purposes, the Company's 2016 through 2022 tax years remain open for examination by the tax authorities under the normal statute of limitations. For certain international income tax purposes, the Company's 2016 through 2022 tax years remain open for examination by the tax authorities under the normal statute of limitations. No provision is made for foreign withholding or income taxes associated with the cumulative undistributed earnings of the foreign subsidiaries. Any future foreign withholding or income taxes associated with the undistributed earnings are not anticipated to be material. The following table provides a reconciliation of the beginning and ending amounts of unrecognized tax benefits, excluding accrued interest (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ December 31, ​ ​ 2022 ​ 2021 Balance at beginning of period ​ $ 175 ​ $ 171 Additions related to current period tax positions ​ ​ 4 ​ ​ 4 Balance at end of period ​ $ 179 ​ $ 175 ​ It is not anticipated that the amount of unrecognized tax benefits will materially change in the next 12 months. If recognized, the total amount of unrecognized tax benefits would have an immaterial impact on the Company’s effective income tax rate. ​ The Company classifies interest expense related to unrecognized tax benefits as components of the income tax expense or benefit. Interest and penalties recognized in the consolidated statements of operations were immaterial.

Related Parties

Related Parties	12 Months Ended
	Dec. 31, 2022
Related Parties
Related Parties	Note 18. Related Parties In August 2022, affiliates of Avista Capital Partners, an entity that holds significant influence over the Company, and two of the Company’s executive officers, one of whom is also a director, among other parties participated in a private placement of ordinary shares at the then-current market trading price (see Note 20). There were no other related party transactions and no related expenses were recognized for the years ended December 31, 2022 and 2021.

Restructuring Expenses

Restructuring Expenses	12 Months Ended
	Dec. 31, 2022
Restructuring Expenses
Restructuring Expenses	Note 19. Restructuring Expenses In April and September 2022, as part of initiatives to refine the Company’s go to market strategy, the Company recognized an aggregate of $2.9 million in expenses primarily associated with employee severance benefits that were classified in selling, general and administrative expenses in the accompanying consolidated financial statements of operations and comprehensive loss. In April 2021, the Company curtailed operations and implemented workforce reductions in its research and development subsidiary in Buenos Aires, Argentina. These restructuring activities were associated with the Company’s plans to reduce expenses and better align business activities with the Company’s corporate strategy. As a result, the Company recognized $4.5 million of restructuring expenses restructuring expenses development expenses, and $1.3 million of asset disposal costs were recognized in non-operating expenses, each in the accompanying statements of operations and comprehensive loss.

Shareholders' Equity and Warran

Shareholders' Equity and Warrant Liabilities	12 Months Ended
	Dec. 31, 2022
Shareholders' Equity and Warrant Liabilities
Shareholders' Equity and Warrant Liabilities	Note 20. Shareholders’ Equity and Warrant Liabilities 2022 Equity Offering As a condition to the effectiveness of the First Amendment (see Note 12), on August 4, 2022 the Company entered into a series of share subscriptions (collectively, the “Share Subscription Agreements”) with Athyrium Opportunities IV Co-Invest 2 LP (“Athyrium”), Avista Healthcare Partners, L.P. (“Avista”), Brian Markison, Chief Executive Officer, and James Schaub, Executive Vice President and Chief Operating Officer, (together, the “Equity Purchasers”) pursuant to which the Company sold and issued to the Equity Purchasers, in a private placement (the “Private Placement”), an aggregate of 15,451,612 ordinary shares of the Company, nominal value $0.01 per share, at a purchase price of $1.55 per Ordinary Share, the closing market trading price on August 4, 2022. Pursuant to the Share Subscription Agreements, the closing of the Private Placement occurred on August 8, 2022. The Company issued and allotted (i) million. Proceeds from the Private Placement were used for working capital and general corporate purposes. The Share Subscription Agreements also provide the Equity Purchasers with certain registration rights. The ordinary shares issued pursuant to the Share Subscription Agreements were registered on the Company’s Registration Statement on Form S-3 (File No. 333-266984), filed with the Securities and Exchange Commission (“SEC”) on August 19, 2022, and declared effective on August 26, 2022. 2021 Equity Offering and Warrants On October 6, 2021, in order to raise capital to fund the Company’s planned expenditures and meet its obligations, the Company initiated a follow-on equity offering for the issuance and allotment of 14,000,000 ordinary shares and warrants to purchase up to an additional 14,000,000 ordinary shares in an underwritten public offering, at a public offering price of $2.50 per share and accompanying warrant less underwriting discounts and commissions. In addition, the Company granted the underwriter a 30-day On October 12, 2021 the Company closed the follow-on offering via the issuance and allotment of 14,000,000 ordinary shares and warrants to purchase 16,100,000 ordinary shares (the “Warrants") raising aggregate gross proceeds of $35.0 million to the Company. $8.8 million of the gross proceeds, equal to the fair value of the Warrants determined using the Black-Scholes Merton option-pricing model, were allocated to the warrants liability, and the remaining proceeds of $26.2 million were allocated to the ordinary shares. The Company incurred a total of $2.6 million in aggregate issuance costs, including $1.9 million attributable to the ordinary share issuance and thereby deducted from proceeds in equity and $0.7 million attributable to the Warrants and thereby recognized as a component of selling, general and administrative expenses in the year ended December 31, 2021. The Warrants are exercisable for the Company’s ordinary shares at any time and may only be exercised for a whole number of ordinary shares at an exercise price of $3.10 per warrant, subject to adjustments as provided under the terms of the form of warrant. Additionally, the holders of Warrants are entitled, prior to exercise, to participate in any dividend or other distribution of the Company’s assets to holders of ordinary shares presuming the Warrants had been exercised. If exercised for cash by the holders, the Warrants would result in additional gross proceeds to the Company of $49.9 million. In the event of a “Fundamental Transaction” (as defined in the form of warrant), the holders of the Warrants have the contingent right to require the Company (or a successor entity) to redeem the Warrants for cash. The Warrants will expire three and one-half years The Warrants are accounted for as liabilities in accordance with ASC 815-40, Derivatives and Hedging-Contracts in Entity’s Own Equity, 2021 Debt Refinancing On October 12, 2021, the Company issued and allotted 6,148,832 of the Company’s ordinary shares, to the purchaser of the Senior Secured Notes for a price of $0.01 per share, pursuant to a Share Subscription Agreement between the Company and Purchaser, dated October 1, 2021. The number of shares issued and allotted to purchaser was equal to $15.0 million divided by the volume weighted average price per ordinary share in the 60 trading days ended October 8, 2021. The ordinary shares were recognized in shareholders’ equity at their fair value at issuance of $12.6 million. The ordinary shares were subsequently registered on the Company's Registration Statement on Form S-3 (File No. 333-260529), filed with the SEC on October 27, 2021 and declared effective on December 9, 2021. 2021 ATM Equity Offerings On September 8, 2021, the Company entered into a sales agreement with Cantor Fitzgerald & Co., (“Cantor”) under which it may offer and sell its ordinary shares having aggregate sales proceeds of up to $75.0 million from time to time through Cantor as its sales agent by any method permitted that is deemed an “at the market offering” as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended, including, without limitation, sales made directly on the Nasdaq Global Select Market or any other existing trading market for the Company’s ordinary shares (each an “ATM Equity Offering"). During the year ended December 31, 2021 the Company sold 146,162 of its ordinary shares under ATM Equity Offerings at the weighted-average price of $3.13, generating aggregate proceeds of $0.5 million and net proceeds of $0.0 million, after deducting commissions and offering expenses payable by us. The Company also incurred a total of $0.4 million in direct issuance costs, which were attributable to the establishment of the sales agreement and in support of sales of ordinary shares by ATM Equity Offerings and therefore were recognized as a reduction of equity. Ordinary Share Repurchase Program In September 2019, the Company’s board of directors authorized the repurchase of up to 5,251,892 ordinary shares pursuant to a share repurchase program. Purchases under the ordinary share repurchase program can be made on the open market or in privately negotiated transactions, with the size and timing of these purchases based on a number of factors, including the price of our ordinary shares, our business and market conditions. The Company retires ordinary shares acquired under the ordinary share repurchase program. The Company did not repurchase any shares during the years ended December 31, 2022 and 2021.

Financial Instruments and Fair

Financial Instruments and Fair Value Measurements	12 Months Ended
	Dec. 31, 2022
Financial Instruments and Fair Value Measurements
Financial Instruments and Fair Value Measurements	Note 21. Financial Instruments and Fair Value Measurements The Company’s financial instruments subject to fair value measurements include cash and cash equivalents, accounts receivable and other receivables, trade accounts payable, accrued liabilities, long-term debt and warrant liabilities. Assets and Liabilities Measured at Fair Value on a Recurring Basis Financial Assets Cash and cash equivalents, generally consisting of investments in interest-bearing money market accounts, are measured at fair value on a recurring basis using Level 1 measurements. Fair value inputs for these investments are considered Level 1 measurements within the fair value hierarchy because money market account fair values are known and observable through daily published floating net asset values. The fair value of the Company’s cash and cash equivalents, being the same as their carrying value, were Financial Liabilities The Company uses a discounted cash flow technique, an income-based approach, to determine the fair value of the Senior Secured Notes. This technique relies upon an assumption of pricing the Senior Secured Notes to their maturity (without mandatory or voluntary prepayments) and incorporates inputs such as contractual repayment terms, maturity, and discount rate. The most significant unobservable input for the Senior Secured Notes is the discount rate which we estimate by performing a yield analysis that relies upon the discount rate observed in the initial issuance of the Senior Secured Notes as well as certain benchmark debt instruments with observable pricing from which we draw conclusions on the change in the discount rate from period to period. The Company uses the Black-Scholes Merton option-pricing model to value the Warrants. This model incorporates transaction details such as the Company’s stock price, contractual terms, maturity, risk free rates, and volatility. The most significant unobservable input for the warrant liabilities is volatility. Given the limited trading volume and period of time the Company’s stock has been traded in an active market, the expected volatility is estimated by taking the average historical price volatility for industry peers, consisting of several public companies in the Company’s industry that are similar in size, stage, or financial leverage, over a period of time commensurate to the expected term of the warrants. The following tables show financial liabilities subject to fair value measurement on a recurring basis and related information on fair values, valuation techniques and unobservable inputs (dollars in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ At December 31, 2022 ​ Financial Instrument ​ Fair Value ​ Valuation Technique ​ Unobservable Inputs Senior Secured Notes ​ $ (55,500) ​ Income Approach - DCF ​ Discount rate ​ 24.6 % ​ ​ ​ ​ ​ ​ ​ Term (in years) ​ 3.8 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Warrants ​ $ (1,951) ​ Black-Scholes Merton ​ Equity volatility ​ 60.0 % ​ ​ ​ ​ ​ ​ ​ Term (in years) ​ 2.3 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ At December 31, 2021 ​ Financial Instrument ​ Fair Value ​ Valuation Technique ​ Unobservable Inputs Senior Secured Notes ​ $ (43,800) ​ Income Approach - DCF ​ Discount rate ​ 17.9 % ​ ​ ​ ​ ​ ​ ​ Term (in years) ​ 4.8 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Warrants ​ $ (3,220) ​ Black-Scholes Merton ​ Equity volatility ​ 65.0 % ​ ​ ​ ​ ​ ​ ​ Term (in years) ​ 3.3 ​ ​ ​ The following table shows changes in the fair value of financial liabilities subject to Level 3 fair value measurements on a recurring basis (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Senior Secured Notes ​ ​ Warrants Balance, At December 31, 2021 ​ $ (43,800) ​ $ (3,220) Principal issuance of second tranche Senior Secured Notes (Note 8) ​ ​ (20,000) ​ ​ - Cash payments for interest ​ ​ 4,843 ​ ​ - Fair value adjustments through earnings (inclusive of related accrued interest expense) ​ ​ 2,857 ​ ​ 1,269 Fair value adjustments through accumulated other comprehensive income or loss ​ ​ (1,700) ​ ​ - Accrued interest (Note 10) ​ ​ 2,300 ​ ​ - Balance, At December 31, 2022 ​ $ (55,500) ​ $ (1,951) ​ ​ Changes in the fair value of debt that is accounted for at fair value, inclusive of related accrued interest expense, are presented as gains or losses in the accompanying consolidated statements of operations and comprehensive loss under change in fair value of debt. The portion of total changes in fair value of debt attributable to changes in instrument-specific credit risk are determined through specific measurement of periodic changes in the discount rate assumption for company-specific credit risk, exclusive of base market changes, and are presented within change in fair value of debt due to change in credit risk, net of tax, a component of comprehensive income or loss in the accompanying consolidated statements of operations and comprehensive loss. ​ No financial liabilities were subject to fair value measurements on a recurring basis prior to October 2021. ​ Non-recurring Fair Value Measurements As part of the Company’s goodwill and intangible asset impairment assessments performed at quarterly intervals or whenever indicators of impairment are identified or when IPR&D assets are placed into service, the Company estimates the fair values of the subject assets using an income approach that utilizes a discounted cash flow model, or, where appropriate, a market approach. Such valuations typically employ assumptions that are based on significant inputs not observable in the market and thus represent Level 3 measurements within the fair value hierarchy. See Note 9 for discussions of relevant non-recurring fair value measurements, significant assumptions and the associated impairment charges recognized when relevant, performed during the years ended December 31, 2022 and 2021.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2022
Subsequent Events.
Subsequent Events	Note 22. Subsequent Events In February 2023, the Company received $5.0 million in cash from Alora related to a contingent milestone payment earned in connection with the sale of the Legacy Business (see Note 4). In March 2023, the Company paid the $5.0 million to the Purchasers in satisfaction of mandatory repayment conditions required under its Amended Note Purchase Agreement (see Note 12), thereby reducing the outstanding principal balance of the second tranche Senior Secured Notes by $4.3 million. ​ On March 8, 2023, the Company entered into a second amendment to the Note Purchase Agreement (the “Second Amendment”) with, among others, the Purchasers and the Administrative Agent, which further amended the Amended Note Purchase Agreement (see Note 12). The Second Amendment provided solely for the immediate reduction of the minimum liquidity requirement from $15.0 million to $12.5 million. Between January and March 2023, the Company received an aggregate of $4.1 million in federal tax refunds related to income taxes paid in prior periods. The Company is continuing to pursue the collection of $1.8 million of additional federal refund claims. In March 2023, the Company amended a lease agreement for its Sayreville, NJ location, the operations site of RVL Pharmacy, to extend the lease for an additional 36 months through December 31, 2026.

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2022
Basis of Presentation and Summary of Significant Accounting Policies
Basis of Presentation	Basis of Presentation
Principles of Consolidation	Principles of Consolidation
Discontinued Operations	Discontinued Operations
Use of Estimates	Use of Estimates
Foreign Currency Translation	Foreign Currency Translation Our subsidiary in Argentina had operated in a highly inflationary environment, as a result, we had previously recognized cumulative foreign currency translation losses in accumulated other comprehensive income (loss) in accordance with U.S. GAAP. During the year ended December 31, 2021, the Company curtailed its operations in Argentina and, upon the related liquidation becoming substantially complete, reclassified all accumulated foreign currency translation losses to selling, general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss.
Cash and Cash Equivalents	Cash and Cash Equivalents
Accounts Receivable and Allowance for Credit Losses	Accounts Receivable and Allowance for Credit Losses —Accounts receivable result primarily from sales of pharmaceutical products and from amounts due under revenue sharing, license and royalty arrangements. Other receivables result primarily from payroll retention credits and other miscellaneous activities. The Company is exposed to credit losses primarily through sales of its products. Accounts receivable are recorded at amortized cost less an allowance for expected credit losses that are not expected to be recovered. The Company’s expected loss methodology for accounts receivable is developed using historical collection experience, a review of the current status of a customer’s trade receivables, and current and future market conditions. Due to the short-term nature of such accounts receivables, the estimated portion thereof that may not be collected is based on the aging of accounts receivable balances and the financial condition of customers. The Company’s monitoring activities include timely account reconciliations, dispute resolution, payment confirmation, consideration of customers’ financial condition and macroeconomic conditions. Balances are written-off when determined to be uncollectible. Except for the allowance for credit losses, which is reflected as part of selling, general and administrative expenses, the provisions for all other customer reserves are reflected as a reduction of revenues in the consolidated statements of operations and comprehensive loss. The Company considered the current and expected future economic and market conditions surrounding a novel strain of the coronavirus, referred to as COVID-19, and determined that its estimate of credit losses was not significantly impacted.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Fair Value Measurement The valuation hierarchy is composed of three levels. The classification within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The levels within the valuation hierarchy are described below: Level 1 — Assets and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs, such as quoted prices in active markets for identical assets or liabilities. Level 2 — Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals. Level 3 — Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities.
Inventories	Inventories
Property, Plant and Equipment	Property, Plant and Equipment ​ ​ ​ ​ Asset category Depreciable life Leasehold improvements Lesser of the useful life of the improvement or the terms of the underlying lease Machinery 3 - 15 years Furniture, fixtures and equipment 3 - 10 years Computer hardware and software 3 - 12 years ​
Goodwill and Indefinite Lived Intangible Assets	Goodwill and Indefinite Lived Intangible Assets st In-Process Research and Development (“IPR&D”) intangible assets represent the value assigned to incomplete Research & Development (“R&D”) projects that principally represent rights to develop and sell a product that the Company has acquired through business combinations or developed internally which, at that time, have not reached technological feasibility. These assets are not amortized but are subject to impairment testing until regulatory approval is obtained and the product is launched, subject to certain specified conditions and management judgment, or abandonment of a project. At the time of any transfer from an IPR&D asset to an amortizing asset an impairment evaluation is performed. The useful life of any resultant amortizing asset is generally determined by identifying the period in which substantially all of the cash flows are expected to be generated. Such assets will be amortized over their respective estimated useful lives. Impairment testing of IPR&D assets requires the development of significant estimates and assumptions involving the determination of estimated net cash flows for each year for each project or product (including net revenues, cost of sales, research and development expenses, selling and marketing costs and other costs which may be allocated), the appropriate discount rate to select in order to measure the risk inherent in each future cash flow stream, the assessment of each asset’s life cycle, the potential regulatory and commercial success risks, and competitive trends impacting each asset and related cash flow stream as well as other factors. The major risks and uncertainties associated with the timely and successful completion of the IPR&D projects include legal risk, market risk and regulatory risk. If applicable, upon abandonment of the IPR&D project, the assets are reduced to zero. IPR&D assets are assessed for impairment on an annual basis as of October 1 st Impairment charges resulting from annual or interim goodwill and indefinite-lived intangible asset impairment assessments, if any, are classified within total operating expenses, in the accompanying consolidated statements of operations and comprehensive loss.
Licensing and Contract Revenue	Product Sales Revenue Recognition, Revenue is recorded at the transaction price, which is the amount of consideration the Company expects to receive in exchange for transferring products to a customer. The Company determines the transaction price based on fixed consideration. The amount of revenue we recognize is equal to the selling price, adjusted for any variable consideration, which included discounts and allowances at the time revenues were recognized. In determining the transaction price, a significant financing component does not exist since the customer typically pays for the product in advance of the transfer of the product or shortly thereafter. Royalty Revenue Licensing Revenue Freight
Business Combinations	Business Combinations Business Combinations Goodwill represents the excess purchase price over the fair value of the tangible net assets and intangible assets acquired in a business combination. Acquisition-related expenses are recognized separately from business combinations and are expensed as incurred. If the business combination provides for contingent consideration, the Company records the contingent consideration at fair value at the acquisition date. Changes in fair value of contingent consideration resulting from events after the acquisition date, such as earn-outs, are recognized as follows: 1) if the contingent consideration is classified as equity, the contingent consideration is not re-measured and its subsequent settlement is accounted for within equity, or 2) if the contingent consideration is classified as a liability, the changes in fair value are recognized in earnings. Purchases of developed products and licenses that are accounted for as an asset acquisition are capitalized as intangible assets and amortized over an estimated useful life. IPR&D assets acquired as part of an asset acquisition are expensed immediately if they have no alternative future uses.
Research and Development Costs	Research and Development Costs
Advertising	Advertising
Share-based Compensation	Share-based Compensation Stock Compensation Share compensation expense is measured at the date of grant, based on the fair value of an award and recognized ratably over its vesting term, which is generally the vesting period on a graded vesting basis. Share compensation expense for awards with vesting conditions other than service are recognized at the time that those conditions will be achieved. Forfeitures of unvested awards are recognized as they occur by reversing any expense previously recorded in the period of forfeiture. The Company typically issues new ordinary shares upon exercise or vesting of awards. The grant date fair value of restricted stock units is based on the market price of ordinary shares as of the grant date. The grant date fair value of stock options and performance stock units is measured using a Black-Scholes Merton option-pricing model and a Monte Carlo simulation model, respectively, using assumptions based on the terms of each award, the expected behavior of grant recipients and peer company data. Expected volatility is calculated based on a weighting of our own stock price volatility and/or the historical stock price trends of similar entities within our industry over a period of time commensurate with the expected term. The risk-free interest rate is based on U.S. Treasury observed market rates continuously compounded over the duration of the expected term. The expected term of stock options is estimated as the midpoint of the weighted average vesting period and the contractual term. The Company accounts for purchases made under its employee share purchase plan using the estimate grant date fair value in accordance with ASC 718. A purchase price discount and look-back feature under the plan cause it to be compensatory and the Company to recognize share compensation expense on a straight-line basis over the requisite service period. The Company values related shares using a Black-Scholes Merton option-pricing model. When share-based compensation arrangements are modified, the modification is treated as an exchange of the original award for a new award with immediate expense recognition for any incremental value. The incremental value, if any, is measured as the excess of the fair value of new award over the fair value of the original award, each based on circumstances and assumptions as of the modification date.
Leasing	Leasing the underlying asset becomes available for use. The Company has elected to account for non-lease components associated with leases and lease components as a single lease component. The Company recognizes a right-of use asset, which represents the Company’s right to use the underlying asset for the lease term, and a lease liability, which represents the present value of the Company’s obligation to make payments arising over the lease term. The present value of the lease payments are calculated using either the implicit interest rate in the lease or an incremental borrowing rate. ​
Income Taxes	Income Taxes The Company recognizes the benefit of an uncertain tax position that it has taken or expects to take on income tax returns it files if such tax position is more likely than not to be sustained on examination by the taxing authorities, based on the technical merits of the position. These tax benefits are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate resolution.
Comprehensive Income or Loss	Comprehensive Income or Loss
Basic and Diluted Earnings or Loss Per Share	Basic and Diluted Earnings or Loss Per Share In periods of cumulative retained earnings, if ever, as a result of the holders of warrants being entitled to dividends (see Note 20), the warrants are participating securities and will be included in the computation of basic and diluted earnings or loss per share following the two-class method.
Segment Reporting	Segment Reporting
Supplemental Cash Flow Disclosures	​ Supplemental Cash Flow Disclosures ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ ​ 2022 2021 Cash paid for: ​ ​ ​ ​ ​ ​ Interest ​ $ 4,890 ​ $ 8,518 Income taxes ​ $ 184 ​ $ 2,361 Non-cash financing activities: ​ ​ ​ ​ ​ ​ Allocation of equity offering proceeds to warrant liability (see Note 20) ​ $ — ​ $ 8,791 Allocation of debt offering proceeds to ordinary shares (see Note 20) ​ $ — ​ $ 9,243 Recognition of financial commitment asset from ordinary share issuance (see Notes 12 & 20) ​ $ — ​ $ 3,361 ​ The Company received $3.1 million in tax refunds during the year ended December 31, 2022 related to income taxes paid in prior periods.
Recently Adopted Accounting Standards	Recently Adopted Accounting Standards In December 2019, the FASB issued Accounting Standards Update No. 2019-12, Income Taxes Topic 740, Simplifying the Accounting for Income Taxes (“ASU 2019-12”). The Company adopted ASU 2019-12 as required effective January 1, 2021. Among other updates to the accounting for income taxes, ASU 2019-12 removed the exception to the incremental approach for intra-period tax allocation when there is a loss from continuing operations and income or a gain from other items. Accordingly, the Company’s loss from continuing operations for the year ended December 31, 2021 does not reflect a tax benefit amounting to $3.2 million that would have been recognized if ASU 2019-12 was not adopted. Recently Issued Accounting Standards In August 2020, the FASB issued Accounting Standards Update 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity ​ There are no other recently issued accounting standards that are expected to have a material impact to the Company’s financial position or results of operations upon adoption.

Basis of Presentation and Sum_3

Basis of Presentation and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2022
Basis of Presentation and Summary of Significant Accounting Policies
Schedule of Useful Lives Of Property, Plant and Equipment	​ ​ ​ ​ Asset category Depreciable life Leasehold improvements Lesser of the useful life of the improvement or the terms of the underlying lease Machinery 3 - 15 years Furniture, fixtures and equipment 3 - 10 years Computer hardware and software 3 - 12 years ​
Schedule of supplemental cash flow disclosures	​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ ​ 2022 2021 Cash paid for: ​ ​ ​ ​ ​ ​ Interest ​ $ 4,890 ​ $ 8,518 Income taxes ​ $ 184 ​ $ 2,361 Non-cash financing activities: ​ ​ ​ ​ ​ ​ Allocation of equity offering proceeds to warrant liability (see Note 20) ​ $ — ​ $ 8,791 Allocation of debt offering proceeds to ordinary shares (see Note 20) ​ $ — ​ $ 9,243 Recognition of financial commitment asset from ordinary share issuance (see Notes 12 & 20) ​ $ — ​ $ 3,361

Discontinued Operations (Tables

Discontinued Operations (Tables)	12 Months Ended
	Dec. 31, 2022
Legacy Products And Manufacturing Facility | Discontinued Operations, Held-for-sale or Disposed of by Sale [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Schedule of results of operations and carrying amounts of assets and liabilities of discontinued operations	​ The following table presents the results of discontinued operations (in thousands): ​ ​ ​ ​ ​ ​ ​ Year Ended ​ ​ ​ December 31, 2021 ​ Total revenues ​ $ 62,395 ​ Cost of goods sold (inclusive of depreciation and amortization) ​ 30,018 ​ Selling, general and administrative expenses ​ 5,468 ​ Research and development expenses ​ ​ 5,882 ​ Income from operations ​ 21,027 ​ Interest expense and amortization of debt discount ​ 6,399 ​ Other non-operating expense, net ​ 1,058 ​ Income from discontinued operations before gain on disposal and provision for income taxes ​ 13,570 ​ Income tax benefit ​ ​ 297 ​ Income from discontinued operations before gain on disposal ​ ​ 13,867 ​ Gain on sales of discontinued operations ​ ​ 4,062 ​ Income from discontinued operations, net of tax ​ $ 17,929 ​ ​ The following table presents the significant non-cash items and purchases of property, plant and equipment for the discontinued operations that are included in the accompanying consolidated statements of cash flows (in thousands): ​ ​ ​ ​ ​ ​ Year Ended Cash flows from operating activities: ​ December 31, 2021 Depreciation and amortization ​ $ 6,583 Share compensation ​ ​ 619 ​ ​ ​ ​ Cash flows from investing activities: ​ ​ ​ Purchases of property, plant and equipment ​ $ (1,335)

Revenues (Tables)

Revenues (Tables)	12 Months Ended
	Dec. 31, 2022
Revenues
Schedule of disaggregation of revenue from contracts with customers	The following table presents disaggregated revenues from contracts with customers (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ ​ 2022 2021 Net product sales - Upneeq ​ $ 34,221 ​ $ 7,511 ​ Royalty and licensing revenue ​ 15,500 ​ ​ 9,990 ​ Total revenues ​ $ 49,721 ​ $ 17,501 ​ ​
Schedule of adjustments to gross product sales	The following table presents the various adjustments recognized against gross product sales (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 2021 Gross product sales ​ $ 35,588 ​ $ 7,997 Less provisions for: ​ ​ ​ ​ ​ Chargebacks ​ (11) ​ ​ (2) Discounts and allowances ​ (1,356) ​ ​ (484) Net product sales ​ $ 34,221 ​ $ 7,511

Accounts Receivable, Other Re_2

Accounts Receivable, Other Receivables, Sales Deductions and Allowances (Tables)	12 Months Ended
	Dec. 31, 2022
Accounts, Notes, Loans and Financing Receivable [Line Items]
Schedule of components of accounts receivable and other receivables	​ The following table presents the components of accounts receivable and other receivables (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ December 31, December 31, ​ ​ 2022 ​ 2021 Trade accounts receivable ​ $ 947 ​ $ — Other receivables ​ 2,084 ​ 2,133 Total accounts receivable and other receivables ​ $ 3,031 ​ $ 2,133 ​
Trade accounts receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Schedule of activity in allowance/liability for customer deductions	The following table presents the periodic activity within various reserves recognized against gross accounts receivable (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Discounts ​ ​ ​ ​ ​ ​ ​ Commercial ​ and ​ ​ ​ ​ ​ Chargebacks ​ Rebates ​ Allowances ​ Total Balance at January 1, 2021 ​ $ — ​ $ 4 ​ $ 1 ​ $ 5 Provision ​ ​ 2 ​ ​ — ​ ​ 484 ​ ​ 486 Charges processed ​ ​ (2) ​ ​ (4) ​ ​ (485) ​ ​ (491) Balance at December 31, 2021 ​ ​ — ​ ​ — ​ ​ — ​ ​ — Provision ​ ​ 11 ​ ​ — ​ ​ 1,356 ​ ​ 1,367 Charges processed ​ ​ (11) ​ ​ — ​ ​ (1,356) ​ ​ (1,367) Balance at December 31, 2022 ​ $ — ​ $ — ​ $ — ​ $ — ​

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2022
Allowance for excess and obsolete inventory
Inventory [Line Items]
Schedule of activity in allowance for inventory valuation and obsolescence	The Company maintains an allowance for excess and obsolete inventory, as well as inventory where its cost is in excess of its net realizable value. The following table presents activity in the allowance for excess and obsolete inventory (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ ​ ​ 2022 ​ ​ 2021 Balance at beginning of period ​ $ 34 ​ $ — Provision ​ (1) ​ 34 Charges processed ​ (31) ​ — Balance at end of period ​ $ 2 ​ $ 34

Property, Plant and Equipment_2

Property, Plant and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment, Net
Schedule of Property, Plant and Equipment	The following table presents the components of property, plant and equipment (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ ​ 2022 2021 Leasehold improvements ​ $ 386 ​ $ 1,129 Machinery ​ ​ 17 ​ ​ — Furniture, fixtures and equipment ​ ​ — ​ ​ 4 Computer hardware and software ​ ​ 1,324 ​ ​ 1,302 ​ ​ 1,727 ​ 2,435 Accumulated depreciation ​ ​ (1,151) ​ ​ (1,641) ​ ​ ​ 576 ​ ​ 794 Construction in progress ​ ​ 700 ​ ​ 72 ​ ​ $ 1,276 ​ $ 866 ​

Goodwill and Indefinite-lived_2

Goodwill and Indefinite-lived Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2022
Goodwill and Indefinite-Lived Intangible Assets
Schedule of changes in carrying value of goodwill	​ ​ ​ ​ ​ ​ Goodwill January 1, 2021 ​ $ 55,847 Impairments ​ ​ — December 31, 2021 ​ ​ 55,847 Impairments ​ ​ — December 31, 2022 ​ $ 55,847

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2022
Accrued Liabilities
Schedule of accrued liabilities	The following table presents the components of accrued liabilities (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ December 31, December 31, ​ ​ 2022 ​ 2021 Accrued expenses and other liabilities ​ $ 5,894 ​ $ 7,897 Accrued compensation ​ ​ 3,908 ​ ​ 4,504 Accrued interest ​ ​ 2,300 ​ ​ — Accrued royalties ​ 1,144 ​ 200 Deferred revenue ​ 1,923 ​ 67 Accrued research and development ​ ​ 226 ​ ​ 409 Total accrued liabilities ​ $ 15,395 ​ $ 13,077

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2022
Leases
Schedule of lease assets and liabilities on the Balance Sheet	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, Leases Classification ​ 2022 ​ 2021 Assets ​ ​ ​ ​ ​ ​ ​ Operating Operating lease assets ​ $ 512 ​ $ 1,368 Finance Property, plant and equipment, net ​ ​ 28 ​ ​ 5 Total leased assets ​ ​ $ 540 ​ $ 1,373 ​ ​ ​ ​ ​ ​ ​ ​ Liabilities ​ ​ ​ ​ ​ ​ ​ Current ​ ​ ​ ​ ​ ​ ​ Operating Current portion of lease liability ​ $ 435 ​ $ 839 Finance Current portion of obligations under finance leases ​ ​ 10 ​ ​ 5 ​ ​ ​ ​ ​ ​ ​ ​ Non-current ​ ​ ​ ​ ​ ​ ​ Operating Long-term portion of lease liability ​ ​ 94 ​ ​ 592 Finance Long-term portion of obligations under finance leases ​ ​ 18 ​ ​ — Total lease liabilities ​ ​ $ 557 ​ $ 1,436 ​
Schedule of lease costs	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, Lease Cost Classification ​ 2022 ​ 2021 Operating lease cost Selling, general and administrative expenses ​ $ 1,111 ​ $ 1,425 ​ Research and development expenses ​ ​ — ​ ​ 28 ​ Cost of goods sold ​ ​ 42 ​ ​ 41 ​ ​ ​ ​ ​ ​ ​ ​ Finance lease cost ​ ​ ​ ​ ​ ​ ​ Amortization of leased assets Cost of goods sold ​ ​ 10 ​ ​ 24 Interest on lease liabilities Interest expense and amortization of debt discount ​ ​ — ​ ​ — Total lease cost ​ ​ $ 1,163 ​ $ 1,518 ​
Schedule of future minimum rental payments ASC842	​ ​ ​ ​ ​ Year Ending December 31, Operating Leases 2023 ​ $ 445 2024 ​ 93 Total lease payments ​ ​ 538 Less: interest ​ ​ 9 Present value of lease payments ​ $ 529 ​
Schedule of additional lease information	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ Lease Term and Discount Rate ​ 2022 ​ 2021 ​ Weighted average remaining lease term (years) ​ ​ ​ ​ ​ ​ ​ Operating leases ​ ​ 1.2 ​ ​ 1.8 ​ Finance leases ​ ​ 2.5 ​ ​ 0.6 ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average discount rate ​ ​ ​ ​ ​ ​ ​ Operating leases ​ ​ 3.56 % ​ 4.15 % Finance leases ​ ​ 10.50 % ​ 2.06 % ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ Other Information ​ 2022 ​ 2021 ​ Cash paid for amounts included in the measurement of lease liabilities: ​ ​ ​ ​ ​ ​ ​ Operating cash flows for operating leases ​ $ (1,153) ​ $ (1,478) ​ Operating cash flows for finance leases ​ ​ (2) ​ ​ — ​ Financing cash flows for finance leases ​ ​ (10) ​ ​ (16) ​ ​

Financing Arrangements (Tables)

Financing Arrangements (Tables)	12 Months Ended
	Dec. 31, 2022
Financing Arrangements
Schedule of Composition of Company's Debt and Financing Obligations	​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ December 31, ​ ​ 2022 ​ 2021 Senior Secured Notes (measured at fair value) ​ $ 55,500 ​ $ 43,800 Note payable — insurance financing ​ 1,432 ​ 2,409 Total debt and financing obligations ​ 56,932 ​ 46,209 Less: current portion of debt ​ (1,432) ​ (2,409) Long-term debt ​ $ 55,500 ​ $ 43,800 ​
Schedule of Maturities of Long-Term Debt	The following table presents the aggregation of principal maturities of long-term debt and financing obligations (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ending December 31, Debt Obligations 2023 ​ $ 1,432 2024 ​ 15,000 2025 ​ ​ 15,000 2026 ​ ​ 45,000 Total future minimum payments ​ ​ 76,432 Less: current portion of debt principal ​ ​ (1,432) Non-current portion of debt principal ​ $ 75,000 ​

Share-Based Compensation (Table

Share-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of valuation assumptions	​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended ​ Year Ended ​ ​ ​ December 31, ​ December 31, ​ ​ 2022 2021 Expected volatility 84 % 81 % Risk-free interest rate 1.63 - 3.78 % 1.25% - 1.29 % Expected dividend yield — % — % Expected life of options in years 6.25 ​ 6.08 - 6.25 ​ ​
Summary of performance share unit activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2018 Plan - PSUs ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted- ​ ​ Weighted- ​ ​ ​ Number of ​ ​ Average Grant ​ ​ Average Remaining ​ ​ ​ PSUs ​ ​ Date Fair Value ​ ​ Term (Years) Outstanding at January 1, 2021 ​ ​ 789,799 ​ $ 4.99 ​ ​ ​ PSUs granted ​ ​ — ​ ​ — ​ ​ ​ PSUs vested ​ ​ — ​ ​ — ​ ​ ​ PSUs forfeited ​ ​ (789,799) ​ ​ 4.99 ​ ​ ​ Outstanding at December 31, 2021 ​ ​ — ​ $ — ​ ​ — ​
Summary of restricted stock unit activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2018 Plan - RSUs ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted- ​ ​ Weighted- ​ ​ ​ Number of ​ ​ Average Grant ​ ​ Average Remaining ​ ​ ​ RSUs ​ ​ Date Fair Value ​ ​ Contractual Term Outstanding at January 1, 2021 ​ ​ 1,991,557 ​ $ 5.99 ​ ​ ​ RSUs granted ​ ​ 161,188 ​ ​ 3.25 ​ ​ ​ RSUs vested ​ ​ (601,306) ​ ​ 6.05 ​ ​ ​ RSUs forfeited ​ ​ (199,164) ​ ​ 4.73 ​ ​ ​ Outstanding at December 31, 2021 ​ ​ 1,352,275 ​ $ 5.82 ​ ​ ​ RSUs granted ​ ​ 75,000 ​ ​ 1.88 ​ ​ ​ RSUs vested ​ ​ (310,783) ​ ​ 5.76 ​ ​ ​ RSUs forfeited ​ ​ (82,843) ​ ​ 5.18 ​ ​ ​ Outstanding at December 31, 2022 ​ ​ 1,033,649 ​ $ 5.60 ​ ​ 1.5 years ​
2016 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Summary of option activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2016 Plan - Share Options ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ Weighted ​ ​ Average ​ ​ ​ Number of ​ Average ​ ​ Remaining ​ ​ Share Options Exercise Price ​ ​ Contractual Term Outstanding at January 1, 2021 ​ ​ 2,827,100 ​ $ 14.95 ​ ​ ​ Granted ​ ​ — ​ ​ — ​ ​ ​ Exercised ​ ​ — ​ ​ — ​ ​ ​ Expired / Forfeited ​ ​ (312,690) ​ $ 14.95 ​ ​ ​ Outstanding at December 31, 2021 ​ ​ 2,514,410 ​ $ 14.95 ​ ​ ​ Vested at December 31, 2021 ​ ​ 2,514,410 $ 14.95 ​ ​ ​ Granted ​ ​ — ​ ​ — ​ ​ ​ Exercised ​ ​ — ​ ​ — ​ ​ ​ Expired / Forfeited ​ ​ (239,874) ​ $ 14.95 ​ ​ ​ Outstanding at December 31, 2022 ​ ​ 2,274,536 ​ $ 14.95 ​ ​ 3.4 years Vested at December 31, 2022 ​ ​ 2,274,536 $ 14.95 ​ ​ 3.4 years ​
Equity Incentive Plan 2018 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Summary of option activity	​ ​ ​ ​ ​ ​ ​ ​ ​ 2018 Plan - Share Options ​ ​ ​ Weighted ​ Weighted ​ ​ ​ ​ Average ​ Average Remaining ​ ​ Number of ​ Exercise ​ Contractual ​ Share Options Price Term Outstanding at January 1, 2021 96,400 ​ $ 7.00 ​ Granted ​ 3,174,886 ​ ​ 1.80 ​ ​ Exercised ​ — ​ ​ — ​ ​ Expired / Forfeited ​ (88,850) ​ $ 5.98 ​ ​ Outstanding at December 31, 2021 ​ 3,182,436 ​ $ 1.84 ​ ​ Vested Options at December 31, 2021 ​ — ​ ​ ​ ​ ​ Granted ​ 114,700 ​ $ 1.24 ​ ​ Exercised ​ — ​ ​ — ​ ​ Expired / Forfeited ​ (796,914) ​ $ 1.82 ​ ​ Outstanding at December 31, 2022 ​ 2,500,222 ​ $ 1.82 ​ 8.8 years Vested Options at December 31, 2022 ​ 659,119 ​ $ 1.94 ​ 8.8 years ​

Earnings or Loss Per Ordinary_2

Earnings or Loss Per Ordinary Share (Tables)	12 Months Ended
	Dec. 31, 2022
Earnings or Loss Per Ordinary Share
Schedule of potentially dilutive securities excluded from computation of diluted weighted average shares	​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2022 2021 Performance and restricted stock units ​ 1,033,649 ​ 1,352,275 Share options to purchase ordinary shares ​ 4,774,758 ​ 5,696,846 Warrants to purchase ordinary shares ​ 16,100,000 ​ 16,100,000 Ordinary shares to be purchased through employee stock purchase plan ​ 96,612 ​ 129,258

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2022
Income Taxes
Schedule of Income Tax Expense	The following table shows the components of loss before income taxes and the related current and deferred income taxes from continuing operations (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ December 31, ​ ​ 2022 ​ 2021 Loss before income taxes ​ ​ U.S. operations ​ $ (48,197) ​ $ (68,975) Non-U.S. operations ​ (3,515) ​ (13,559) Total loss before income taxes ​ (51,712) ​ (82,534) Current income tax expense (benefit) ​ ​ Federal ​ 86 ​ 192 State ​ 105 ​ (41) Foreign ​ (68) ​ 20 Total current income tax expense (benefit) ​ 123 ​ 171 Deferred income tax expense (benefit) ​ ​ Federal ​ (90) ​ 149 Foreign ​ (53) ​ (5) Total deferred income tax expense (benefit) ​ (143) ​ 144 Total income tax expense (benefit) ​ $ (20) ​ $ 315 ​
Schedule Reconciling Statutory Tax Rate to Effective Tax Rate	​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ December 31, ​ ​ 2022 ​ 2021 U.S. federal income tax at 21% statutory rate 21.00 % 21.00 % State and local income taxes, net of federal benefit 6.28 % 2.65 % Differences in tax effects on foreign income 0.23 % 8.81 % Federal tax credits 0.95 % 0.29 % Uncertain tax positions (0.01) % — % NOL carryback rate differential ​ — % (0.03) % Tax audit adjustments ​ 0.11 % 0.01 % Change in valuation allowance (23.24) % (33.83) % Permanent adjustments (0.63) % (0.01) % Return to provision ​ (4.65) % — % Other — % 0.73 % Effective income tax rate 0.04 % (0.38) % ​
Schedule of Deferred Tax Assets and Liabilities	​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ December 31, ​ ​ 2022 ​ 2021 Deferred tax assets: ​ ​ Accrued expenses ​ $ 714 ​ $ 827 Inventories ​ 4 ​ — Net operating losses ​ 26,944 ​ ​ 21,134 Capital losses ​ ​ 23,805 ​ ​ 23,845 Right of use liabilities ​ 120 ​ 340 Tax credits ​ ​ 8,207 ​ ​ 7,232 Debt costs ​ ​ 3,311 ​ ​ 4,740 Interest expense ​ ​ 4,367 ​ ​ 2,168 Share compensation ​ ​ 709 ​ ​ 285 Other ​ 3,561 ​ 2,916 Less: valuation allowance ​ (64,872) ​ (52,853) Deferred tax liabilities: ​ ​ ​ ​ Property plant & equipment ​ (28) ​ — Intangible assets ​ ​ (2,339) ​ ​ (6,353) Debt costs ​ ​ (4,447) ​ ​ (4,107) Right of use assets ​ (117) ​ (325) Total deferred income taxes ​ $ (61) ​ $ (151)
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]	The following table provides a reconciliation of the beginning and ending amounts of unrecognized tax benefits, excluding accrued interest (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ December 31, ​ ​ 2022 ​ 2021 Balance at beginning of period ​ $ 175 ​ $ 171 Additions related to current period tax positions ​ ​ 4 ​ ​ 4 Balance at end of period ​ $ 179 ​ $ 175 ​

Financial Instruments and Fai_2

Financial Instruments and Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2022
Financial Instruments and Fair Value Measurements
Schedule of valuation techniques and unobservable inputs	The following tables show financial liabilities subject to fair value measurement on a recurring basis and related information on fair values, valuation techniques and unobservable inputs (dollars in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ At December 31, 2022 ​ Financial Instrument ​ Fair Value ​ Valuation Technique ​ Unobservable Inputs Senior Secured Notes ​ $ (55,500) ​ Income Approach - DCF ​ Discount rate ​ 24.6 % ​ ​ ​ ​ ​ ​ ​ Term (in years) ​ 3.8 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Warrants ​ $ (1,951) ​ Black-Scholes Merton ​ Equity volatility ​ 60.0 % ​ ​ ​ ​ ​ ​ ​ Term (in years) ​ 2.3 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ At December 31, 2021 ​ Financial Instrument ​ Fair Value ​ Valuation Technique ​ Unobservable Inputs Senior Secured Notes ​ $ (43,800) ​ Income Approach - DCF ​ Discount rate ​ 17.9 % ​ ​ ​ ​ ​ ​ ​ Term (in years) ​ 4.8 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Warrants ​ $ (3,220) ​ Black-Scholes Merton ​ Equity volatility ​ 65.0 % ​ ​ ​ ​ ​ ​ ​ Term (in years) ​ 3.3 ​ ​ ​
Schedule of financial liabilities subject to Level 3 fair value measurements on a recurring basis	The following table shows changes in the fair value of financial liabilities subject to Level 3 fair value measurements on a recurring basis (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Senior Secured Notes ​ ​ Warrants Balance, At December 31, 2021 ​ $ (43,800) ​ $ (3,220) Principal issuance of second tranche Senior Secured Notes (Note 8) ​ ​ (20,000) ​ ​ - Cash payments for interest ​ ​ 4,843 ​ ​ - Fair value adjustments through earnings (inclusive of related accrued interest expense) ​ ​ 2,857 ​ ​ 1,269 Fair value adjustments through accumulated other comprehensive income or loss ​ ​ (1,700) ​ ​ - Accrued interest (Note 10) ​ ​ 2,300 ​ ​ - Balance, At December 31, 2022 ​ $ (55,500) ​ $ (1,951) ​

Basis of Presentation - Propert

Basis of Presentation - Property, plant and equipment (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Foreign currency transaction gains	$ 0.1	$ 1.4
Minimum | Machinery
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Minimum | Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Minimum | Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Maximum | Machinery
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	15 years
Maximum | Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Maximum | Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	12 years

Basis of Presentation - IPR&D,

Basis of Presentation - IPR&D, Advertising (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Marketing and Advertising Expense [Abstract]
Advertising expense	$ 15.9	$ 14.9

Basis of Presentation - Long-li

Basis of Presentation - Long-lived assets (Details)	12 Months Ended
	Dec. 31, 2022 USD ($) item	Dec. 31, 2021 USD ($)
Impaired Long-Lived Assets Held and Used [Line Items]
Impairment of intangible assets	$ 13,310,000	$ 7,880,000
Number of reporting units | item	1
Goodwill impairment	$ 0	0
In-Process Research and Development project
Impaired Long-Lived Assets Held and Used [Line Items]
Impairment of intangible assets	$ 13,300,000	$ 7,900,000

Basis of Presentation - Segment

Basis of Presentation - Segments (Details)	12 Months Ended
	Dec. 31, 2022 segment
Basis of Presentation and Summary of Significant Accounting Policies
Number of operating segments	1
Number of reportable operating segments	1

Basis of Presentation and Sum_4

Basis of Presentation and Summary of Significant Accounting Policies - Supplemental Cash Flow Disclosures (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash paid for:
Interest	$ 4,890	$ 8,518
Income taxes	184	2,361
Non-cash financing activities:
Allocation of equity offering proceeds to warrant liability (see Note 20)		8,791
Allocation of debt offering proceeds to ordinary shares (see Note 20)		9,243
Recognition of financial commitment asset from ordinary share issuances (see Notes 12 & 20)		3,361
Income tax refunds	$ 3,100
Releases related to prior period tax positions		$ 3,200

Liquidity (Details)

Liquidity (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Liquidity
Cash and cash equivalents	$ 44,543	$ 40,444	$ 114,053
Accumulated deficit	(569,222)	(517,530)
Long-term Debt, Gross	75,000
Net loss from continuing operations	(51,692)	(82,849)
Cash used from operating activities	$ 37,810	$ 54,732

Discontinued Operations - Gain

Discontinued Operations - Gain on Sale (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2021 USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash proceeds	$ 110,845
Gain on sale, pre-tax	4,062
Legacy Products And Manufacturing Facility | Discontinued Operations, Held-for-sale or Disposed of by Sale [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain on sale, pre-tax	$ 4,062

Discontinued Operations (Detail

Discontinued Operations (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Aug. 27, 2021
Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]
Gain on sales of discontinued operations		$ 4,062
Income from discontinued operations, net of tax		17,929
Legacy Products And Manufacturing Facility | Discontinued Operations, Held-for-sale or Disposed of by Sale [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Consideration			$ 111,000
Additional milestone payments			$ 60,000
Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]
Total revenues		62,395
Cost of goods sold (inclusive of depreciation and amortization)		30,018
Selling, general and administrative expenses		5,468
Research and development expenses		5,882
Income from operations		21,027
Interest expense and amortization of debt discount		6,399
Other non-operating expense, net		1,058
Income from discontinued operations before gain on disposal and provision for income taxes		13,570
Income tax benefit		297
Income from discontinued operations before gain on disposal		13,867
Gain on sales of discontinued operations		4,062
Income from discontinued operations, net of tax		$ 17,929
Alora Pharmaceuticals, Llc | Discontinued Operations, Held-for-sale or Disposed of by Sale [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Contingent milestone payments earned	$ 5,000

Discontinued Operations - Cash

Discontinued Operations - Cash flows (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash Flows from Investing Activities:
Purchases of property, plant and equipment	$ (752)	$ (1,782)
Legacy Products And Manufacturing Facility | Discontinued Operations, Held-for-sale or Disposed of by Sale [Member]
Cash Flows from Operating Activities:
Depreciation and amortization		6,583
Share compensation		619
Cash Flows from Investing Activities:
Purchases of property, plant and equipment		$ (1,335)

Revenues (Details)

Revenues (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disaggregation of Revenue [Line Items]
Total revenues	$ 49,721	$ 17,501
Contract with customer, asset and liability
Contract assets	0	0
Upneeq
Disaggregation of Revenue [Line Items]
Total revenues	34,221	7,511
Royalty and licensing revenue
Disaggregation of Revenue [Line Items]
Total revenues	$ 15,500	$ 9,990

Revenues - Adjustment to gross

Revenues - Adjustment to gross product sales (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disaggregation of Revenue [Line Items]
Gross product sales	$ 35,588	$ 7,997
Revenues	49,721	17,501
Chargebacks
Disaggregation of Revenue [Line Items]
Adjustments to gross products sales	(11)	(2)
Discounts and allowances
Disaggregation of Revenue [Line Items]
Adjustments to gross products sales	(1,356)	(484)
Net product sales
Disaggregation of Revenue [Line Items]
Revenues	$ 34,221	$ 7,511

Revenues - Narrative (Details)

Revenues - Narrative (Details) - USD ($) $ in Millions		12 Months Ended
	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021
Maximum
Disaggregation of Revenue [Line Items]
Revenue recognized		$ 0.1	$ 0.1
Santen Pharmaceutical Co. Ltd. | Exercise of option to expand the territories to include Russia
Disaggregation of Revenue [Line Items]
Upfront cash payment	$ 2
Developmental and regulatory cash milestone payments	1
Santen Pharmaceutical Co. Ltd. | Maximum
Disaggregation of Revenue [Line Items]
Developmental and regulatory cash milestone payments	1
License Agreement | Santen Pharmaceutical Co. Ltd.
Disaggregation of Revenue [Line Items]
Upfront cash payment	$ 15.5
Period of option to expand territories following amendment date	5 years

Accounts Receivable, Other Re_3

Accounts Receivable, Other Receivables, Sales Deductions and Allowances (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Accounts Receivable, Other Receivables, Sales Deductions and Allowances
Trade accounts receivable	$ 947
Other receivables	2,084	$ 2,133
Total accounts receivable and other receivables	$ 3,031	$ 2,133

Accounts Receivable, Other Re_4

Accounts Receivable, Other Receivables, Sales Deductions and Allowances - Allowance for customer deduction (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Charges processed	$ (1,367)	$ (491)
Trade accounts receivable
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at beginning of period		5
Provision	1,367	486
Chargebacks
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Charges processed	(11)	(2)
Chargebacks | Trade accounts receivable
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Provision	11	2
Commercial rebates
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Charges processed		(4)
Commercial rebates | Trade accounts receivable
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at beginning of period		4
Discounts and allowances
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Charges processed	(1,356)	(485)
Discounts and allowances | Trade accounts receivable
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at beginning of period		1
Provision	$ 1,356	$ 484

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Inventories
Inventories, net	$ 784	$ 838
Summary of activity in the allowance for excess, obsolete, and net realizable value inventory account
Charges processed	(1,367)	(491)
Allowance for excess and obsolete inventory
Summary of activity in the allowance for excess, obsolete, and net realizable value inventory account
Balance at beginning of period	34
Provision	(1)	34
Charges processed	(31)
Balance at end of period	$ 2	$ 34

Property, Plant and Equipment_3

Property, Plant and Equipment, Net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross, excluding construction in progress	$ 1,727	$ 2,435
Accumulated depreciation	(1,151)	(1,641)
Property, plant and equipment, excluding construction in progress	576	794
Construction in progress	700	72
Property, plant and equipment, net	1,276	866
Depreciation expense	400	1,500
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross, excluding construction in progress	386	1,129
Machinery
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross, excluding construction in progress	17
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross, excluding construction in progress		4
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross, excluding construction in progress	$ 1,324	$ 1,302

Goodwill and Indefinite-lived_3

Goodwill and Indefinite-lived Intangible Assets - Goodwill (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Goodwill and Indefinite-Lived Intangible Assets
Goodwill, accumulated impairment	$ 47,800,000	$ 47,800,000
Goodwill [Roll Forward]
Goodwill, accumulated impairment	47,800,000	47,800,000
Goodwill net, Beginning Balance	55,847,000	55,847,000
Impairments	0	0
Goodwill net, Ending Balance	$ 55,847,000	$ 55,847,000

Goodwill and Indefinite-Lived_4

Goodwill and Indefinite-Lived Intangible Assets - Indefinite-Lived Intangible Assets (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Indefinite-lived Intangible Assets [Line Items]
Impairment of intangible assets	$ 13,310	$ 7,880
In-Process Research and Development project
Indefinite-lived Intangible Assets [Line Items]
Carrying value	64,000	64,000
Aggregate impairment losses	50,100	36,800
Net carrying amounts	13,900	27,200
Impairment of intangible assets	$ 13,300	$ 7,900
In-Process Research and Development project | Discount rate
Indefinite-lived Intangible Assets [Line Items]
Intangible Asset Measurement Input	0.175	0.125
In-Process Research and Development project | Measurement Input Discount for Lack of Marketability
Indefinite-lived Intangible Assets [Line Items]
Intangible Asset Measurement Input	0.696

Accrued Liabilities (Details)

Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Accrued Liabilities
Accrued expenses and other liabilities	$ 5,894	$ 7,897
Accrued compensation	3,908	4,504
Accrued interest	2,300
Accrued royalties	1,144	200
Deferred revenue	1,923	67
Accrued research and development	226	409
Total accrued liabilities	$ 15,395	$ 13,077

Leases (Details)

Leases (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Lessee, Lease, Description [Line Items]
Operating Lease, Right-of-Use Asset	$ 512	$ 1,368
Finance Lease, Right-of-Use Asset	$ 28	$ 5
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	Property, Plant And Equipment And Finance Lease Right Of Use Asset, Net Of Accumulated Depreciation	Property, Plant And Equipment And Finance Lease Right Of Use Asset, Net Of Accumulated Depreciation
Total leased assets	$ 540	$ 1,373
Operating Lease, Liability, Current	435	839
Finance Lease, Liability, Current	10	5
Operating Lease, Liability, Noncurrent	94	592
Finance Lease, Liability, Noncurrent	18
Total lease liabilities	$ 557	$ 1,436
Minimum
Lessee, Lease, Description [Line Items]
Remaining lease term	10 months 24 days
Maximum
Lessee, Lease, Description [Line Items]
Remaining lease term	1 year 6 months

Leases - Lease cost (Details)

Leases - Lease cost (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Lease, Cost [Abstract]
Total lease cost	$ 1,163	$ 1,518
Selling, general and administrative expenses
Lease, Cost [Abstract]
Operating lease cost	1,111	1,425
Research and development
Lease, Cost [Abstract]
Operating lease cost		28
Cost of goods sold
Lease, Cost [Abstract]
Operating lease cost	42	41
Amortization of leased assets	$ 10	$ 24

Leases - Maturities (Details)

Leases - Maturities (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Lessee, Operating Lease, Liability, Payment, Due [Abstract]
2023	$ 445
2024	93
Total lease payments	538
Less: interest	9
Present value of lease payments	$ 529

Leases - Additional information

Leases - Additional information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Lease, Cost [Abstract]
Weighted average remaining lease term, operating leases	1 year 2 months 12 days	1 year 9 months 18 days
Weighted average remaining lease term, finance leases	2 years 6 months	7 months 6 days
Weighted average discount rate, operating leases	3.56%	4.15%
Weighted average discount rate, finance leases	10.50%	2.06%
Operating cash flows from operating leases	$ (1,153)	$ (1,478)
Operating cash flows from finance leases	(2)
Financing cash flows from finance leases	(10)	(16)
Leased assets obtained in exchange for new operating lease liabilities	100	700
Disposal, leased assets	$ 100	$ 100

Financing Arrangements - Compon

Financing Arrangements - Components (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Financing Arrangements
Total debt and financing obligations	$ 56,932	$ 46,209
Less: current portion of debt principal	(1,432)	(2,409)
Long-term debt	55,500	43,800
Senior Secured Notes (measured at fair value)
Financing Arrangements
Total debt and financing obligations	55,500	43,800
Note payable - insurance financing
Financing Arrangements
Total debt and financing obligations	$ 1,432	$ 2,409

Financing Arrangements - Maturi

Financing Arrangements - Maturities of long-term debt and financing obligations (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Long-term Debt, Fiscal Year Maturity [Abstract]
2023	$ 1,432
2024	15,000
2025	15,000
2026	45,000
Total future minimum payments	76,432
Less: current portion of debt principal	(1,432)	$ (2,409)
Non-current portion of debt principal	$ 75,000

Financing Arrangements (Details

Financing Arrangements (Details) - USD ($) $ in Thousands							1 Months Ended	6 Months Ended	12 Months Ended
	Aug. 08, 2022	Oct. 12, 2021	Oct. 11, 2021	Oct. 01, 2021	Aug. 27, 2021	Jun. 25, 2021	Aug. 31, 2022	Jun. 30, 2021	Dec. 31, 2022	Dec. 31, 2021	Mar. 31, 2023
Financing Arrangements
Minimum Restricted Cash and Cash Equivalent to be Maintained									$ 15,000
Financial commitment asset										$ 3,063
Net proceeds		$ 26,200	$ 49,900						23,634	32,414
Write off of deferred financing and loan origination fees										1,462
Debt repayment										221,360
Total debt and financing obligations									76,432
Upneeq
Financing Arrangements
Minimum Restricted Cash and Cash Equivalent to be Maintained									55,000
Quarterly Increment in Revenue									1,000
Quarter ending March 31, 2023 | Upneeq
Financing Arrangements
Minimum Quarterly Revenue Threshold Limit									7,000
Quarter ending June 30, 2024 and thereafter | Upneeq
Financing Arrangements
Minimum Quarterly Revenue Threshold Limit									12,000
Alora Pharmaceuticals, Llc | Disposal Group, Not Discontinued Operations [Member]
Financing Arrangements
Waiver of principal									5,000
Consent fee									200
Net proceeds									$ 4,800
Senior Secured Notes Under Note Purchase Agreement [Member]
Financing Arrangements
Interest rate									12%
Debt issuance costs										2,100
Percentage of period payments of outstanding principal amount				5%
Exit fee (as a percent)				2%
Debt repayment		30,000
Senior Secured Notes Under Note Purchase Agreement [Member] | Selling, general and administrative expenses
Financing Arrangements
Write off of deferred financing and loan origination fees										1,500
Senior Secured Notes Under Note Purchase Agreement [Member] | SOFR floor
Financing Arrangements
Margin rate, as a percent	1.50%
Senior Secured Notes Under Note Purchase Agreement, Tranche One [Member]
Financing Arrangements
Face amount of debt		55,000
Interest rate	9%
Debt issuance costs										1,500
Senior Secured Notes Under Note Purchase Agreement, Tranche One [Member] | SOFR cap
Financing Arrangements
Margin rate, as a percent	3%
Senior Secured Notes Under Note Purchase Agreement, Tranche Two [Member]
Financing Arrangements
Face amount of debt	$ 20,000
Debt issuance costs										600
Financial Commitment Asset, Amortization Period									1 year
Financial commitment asset										3,100
Financial Commitment Asset, Amortization Expense									$ 3,100
Senior Secured Notes Under Note Purchase Agreement, Tranche Two [Member] | Subsequent Events
Financing Arrangements
Face amount of debt											$ 4,300
Senior Secured Notes Under Note Purchase Agreement, Tranche Two [Member] | Selling, general and administrative expenses
Financing Arrangements
Write off of deferred financing and loan origination fees							$ 900
Senior Secured Notes Under Note Purchase Agreement, Tranche Two [Member] | Maximum | Upneeq
Financing Arrangements
Face amount of debt									20,000
Senior Secured Notes Under Note Purchase Agreement, Tranche Three [Member]
Financing Arrangements
Face amount of debt	$ 25,000
Minimum Restricted Cash and Cash Equivalent to be Maintained									12,500
Senior Secured Notes Under Note Purchase Agreement, Tranche Three [Member] | Maximum | Upneeq
Financing Arrangements
Face amount of debt									$ 25,000
Prior term loans
Financing Arrangements
Face amount of debt		327,500
Write off of deferred financing and loan origination fees										$ 1,500
Amount outstanding		$ 50,000
Debt repayment					$ 186,100			$ 5,300
Debt Instrument, Termination Upon Signing Of Fifth Amendment, Percentage						50%
Debt Instrument, Termination Upon Legacy Business Divestiture, Percentage						50%
Total debt and financing obligations						$ 30,000

Concentrations and Credit Risk

Concentrations and Credit Risk (Details) - customer	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Trade Accounts Receivable. | Customer concentration risk | Customer One
Concentrations and Credit Risk
Number of customers	1
Concentration risk (as a percent)	94%
Net product sales | Gross Sales | Product Concentration Risk [Member]
Concentrations and Credit Risk
Concentration risk (as a percent)	100%	100%

Share-Based Compensation (Detai

Share-Based Compensation (Details) - USD ($)		12 Months Ended
	Jan. 05, 2023	Dec. 31, 2022	Dec. 31, 2021
Equity, Class of Treasury Stock [Line Items]
Maximum deduction per pay period		$ 2,000
Share price, as percentage of fair market value		85%
Share-based compensation expense		$ 3,900,000	$ 6,800,000
ESPP expense recognized		$ 167,731	$ 134,077
ESPP, shares issued during the period		207,903	76,432
Maximum number of shares per employee amount		$ 25,000
Share options to purchase ordinary shares
Equity, Class of Treasury Stock [Line Items]
Unrecognized compensation cost, recognition period		1 year 7 months 6 days
Restricted stock units
Equity, Class of Treasury Stock [Line Items]
Unrecognized compensation expense		$ 1,900,000
Unrecognized compensation cost, recognition period		1 year 6 months
2016 Equity Incentive Plan
Equity, Class of Treasury Stock [Line Items]
Shares available for future issuance		0
Equity Incentive Plan 2018 [Member]
Equity, Class of Treasury Stock [Line Items]
Shares available for future issuance		0
Employee Share Purchase Plan 2019 [Member]
Equity, Class of Treasury Stock [Line Items]
Unrecognized compensation expense		$ 0	$ 0
Subsequent Events
Equity, Class of Treasury Stock [Line Items]
ESPP, shares issued during the period	96,612

Share-Based Compensation - Opti

Share-Based Compensation - Options (Details) - Share options to purchase ordinary shares - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Weighted Average Exercise Price, Options
Unrecognized compensation cost related to nonvested options	$ 1,200,000
Unrecognized compensation cost, recognition period	1 year 7 months 6 days
Equity Incentive Plan 2018 [Member]
Number of Options
Outstanding at the beginning of period	3,182,436	96,400
Granted	114,700	3,174,886
Expired / Forfeited	(796,914)	(88,850)
Outstanding at at the end of period	2,500,222	3,182,436
Vested options at end of period, number	659,119
Weighted Average Exercise Price, Options
Outstanding at the beginning of period	$ 1.84	$ 7
Granted	1.24	1.80
Expired / Forfeited	1.82	5.98
Outstanding at at the end of period	1.82	1.84
Vested options at the end of period, exercise price	$ 1.94
Options outstanding, weighted average remaining contractual term	8 years 9 months 18 days
Options vested, weighted average contractual term	8 years 9 months 18 days
Weighted average grant date fair value of options granted	$ 1.24	$ 1.25
Options outstanding, intrinsic value	$ 0
Options vested in period, fair value	$ 0	$ 0
2016 Equity Incentive Plan
Number of Options
Outstanding at the beginning of period	2,514,410	2,827,100
Expired / Forfeited	(239,874)	(312,690)
Outstanding at at the end of period	2,274,536	2,514,410
Vested options at end of period, number	2,274,536	2,514,410
Weighted Average Exercise Price, Options
Outstanding at the beginning of period	$ 14.95	$ 14.95
Expired / Forfeited	14.95	14.95
Outstanding at at the end of period	14.95	14.95
Vested options at the end of period, exercise price	$ 14.95	$ 14.95
Options outstanding, weighted average remaining contractual term	3 years 4 months 24 days
Options vested, weighted average contractual term	3 years 4 months 24 days
Options outstanding, intrinsic value	$ 0	$ 0

Share-Based Compensation - Valu

Share-Based Compensation - Valuation Assumptions (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Expected life of options in years	6 years 3 months
Equity Incentive Plan 2018 [Member] | Share options to purchase ordinary shares
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Expected volatility	84%	81%
Risk-free interest rate, minimum	1.63%	1.25%
Risk-free interest rate, maximum	3.78%	1.29%
Equity Incentive Plan 2018 [Member] | Share options to purchase ordinary shares | Minimum
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Expected life of options in years		6 years 29 days
Equity Incentive Plan 2018 [Member] | Share options to purchase ordinary shares | Maximum
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Expected life of options in years		6 years 3 months

Share-Based Compensation - Rest

Share-Based Compensation - Restricted and Performance Stock Units (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 3.9	$ 6.8
Performance stock units | Equity Incentive Plan 2018 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Outstanding at beginning of period, shares		789,799
Forfeited		(789,799)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Grant date fair value, shares outstanding at beginning of period		$ 4.99
Grant date fair value, shares forfeited		$ 4.99
Remaining contractual term		0 years
Restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense	$ 1.9
Unrecognized compensation cost, recognition period	1 year 6 months
Restricted stock units | Director [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Grant date fair value, shares outstanding at beginning of period	$ 3.25
Grant date fair value, shares outstanding at end of period	$ 1.88	$ 3.25
Restricted stock units | Director [Member] | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	1 year
Restricted stock units | Director [Member] | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Restricted stock units | Employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years
Restricted stock units | Equity Incentive Plan 2018 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Outstanding at beginning of period, shares	1,352,275	1,991,557
Granted	75,000	161,188
Vested	(310,783)	(601,306)
Forfeited	(82,843)	(199,164)
Outstanding at end of period, shares	1,033,649	1,352,275
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Grant date fair value, shares outstanding at beginning of period	$ 5.82	$ 5.99
Grant date fair value, shares granted	1.88	3.25
Grant date fair value, shares vested	5.76	6.05
Grant date fair value, shares forfeited	5.18	4.73
Grant date fair value, shares outstanding at end of period	$ 5.60	$ 5.82
Remaining contractual term	1 year 6 months

Earnings or Loss Per Ordinary_3

Earnings or Loss Per Ordinary Share (Details) - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Performance and restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities	1,033,649	1,352,275
Share options to purchase ordinary shares
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities	4,774,758	5,696,846
Warrants to purchase ordinary shares
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities	16,100,000	16,100,000
Ordinary shares to be purchased through employee stock purchase plan
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities	96,612	129,258

Commitments and Contingencies -

Commitments and Contingencies - Legal (Details) $ in Thousands				1 Months Ended	12 Months Ended
	Nov. 10, 2021 USD ($)	Apr. 19, 2021 item	Dec. 02, 2020 USD ($)	Jan. 31, 2021 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Jul. 22, 2019 item
Loss Contingencies [Line Items]
Aggregate milestones payable					$ 800
Proceeds from product rights disposal			$ 7,500			$ 7,300
Gain on sales of product rights, net				$ 5,600		5,636
Agreement Term					6 years
Agreement Extension Period					2 years
Number of claims | item							2
Settlement to be paid	$ 5,250
Number of defendants | item		4
Number of states seeking damages | item		29
Cost of goods sold
Loss Contingencies [Line Items]
Contingent payments					$ 2,800	$ 500

Commitments and Contingencies_2

Commitments and Contingencies - Defined contribution plan (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Defined Contribution Plan Disclosure [Line Items]
Employer match percentage when employee contributes below threshold	100%
Employee contribution threshold, as a percent of basic compensation	3%
Employer match percentage when employee contributes above threshold	50%
Recognized expenses	$ 0.7	$ 0.7
Minimum
Defined Contribution Plan Disclosure [Line Items]
Maximum contribution that employer will match, as a percent	3%
Maximum
Defined Contribution Plan Disclosure [Line Items]
Maximum contribution that employer will match, as a percent	5%

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Taxes
Effective income tax rate	(21.00%)	(21.00%)
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]
U.S. operations	$ (48,197)	$ (68,975)
Non-U.S. operations	(3,515)	(13,559)
Total loss before income taxes	(51,712)	(82,534)
Current income tax expense (benefit) - continuing operations
Federal	86	192
State	105	(41)
Foreign	(68)	20
Total current income tax expense (benefit)	123	171
Deferred income tax expense (benefit) - continuing operations
Federal	(90)	149
Foreign	(53)	(5)
Total deferred income tax expense (benefit)	143	(144)
Total income tax expense (benefit)	$ (20)	$ 315

Income Taxes - Rate reconciliat

Income Taxes - Rate reconciliation (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Effective Income Tax Rate Reconciliation, Percent [Abstract]
U.S. federal income tax at 21% statutory rate	21%	21%
State and local income taxes, net of federal benefit	6.28%	2.65%
Differences in tax effects on foreign income	0.23%	8.81%
Federal tax credits	0.95%	0.29%
Uncertain tax positions	(0.01%)
NOL carryback rate differential		(0.03%)
Tax audit adjustments	0.11%	0.01%
Change in valuation allowance	(23.24%)	(33.83%)
Permanent adjustments	(0.63%)	(0.01%)
Return to provision	(4.65%)
Other		0.73%
Effective income tax rate	0.04%	(0.38%)

Income Taxes - Deferred Tax Ass

Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Components of Deferred Tax Assets [Abstract]
Accrued expenses	$ 714	$ 827
Inventories	4
Net operating losses	26,944	21,134
Capital losses	23,805	23,845
Right of use liabilities	120	340
Tax credits	8,207	7,232
Debt costs	3,311	4,740
Interest expenses	4,367	2,168
Share compensation	709	285
Other	3,561	2,916
Less: valuation allowance	(64,872)	(52,853)
Components of Deferred Tax Liabilities [Abstract]
Property plant & equipment	(28)
Intangible assets	(2,339)	(6,353)
Debt costs	(4,447)	(4,107)
Right of use assets	(117)	(325)
Total deferred income taxes	$ (61)	$ (151)

Income Taxes - Carryovers and a

Income Taxes - Carryovers and allowances (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Line Items]
Tax credit carryforwards	$ 8.6
Increase in valuation allowance	12	$ 25.1
Domestic Tax Authority [Member]
Income Tax Disclosure [Line Items]
Net operating loss carryforward	70.2
Capital loss carryforwards	95.8
State and Local Jurisdiction [Member]
Income Tax Disclosure [Line Items]
Net operating loss carryforward	139.2
Foreign Tax Authority [Member]
Income Tax Disclosure [Line Items]
Net operating loss carryforward	$ 109.9

Income Taxes - Unrecognized tax

Income Taxes - Unrecognized tax benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Balance at beginning of period	$ 175	$ 171
Additions related to current period tax positions	4	4
Balance at end of period	$ 179	$ 175

Related Parties (Details)

Related Parties (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Related Parties
Accrued liability	$ 0	$ 0
Related party expenses	$ 0	$ 0

Restructuring Expenses (Details

Restructuring Expenses (Details) - USD ($) $ in Millions	1 Months Ended		12 Months Ended
	Sep. 30, 2022	Apr. 30, 2022	Dec. 31, 2021
Restructuring Cost and Reserve [Line Items]
Restructuring expenses			$ 4.5
Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]			Nonoperating Income (Expense), Research and Development Expense, Selling, General and Administrative Expense
Selling, general and administrative expenses
Restructuring Cost and Reserve [Line Items]
Severance benefits	$ 2.9	$ 2.9
Special Termination Benefits [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring expenses			$ 3.2
Selling, general and administrative expenses
Restructuring Cost and Reserve [Line Items]
Restructuring expenses			2
Research and development
Restructuring Cost and Reserve [Line Items]
Restructuring expenses			1.2
Facility Closing [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring expenses			1.3
Non-operating expenses
Restructuring Cost and Reserve [Line Items]
Restructuring expenses			$ 1.3

Shareholders' Equity and Warr_2

Shareholders' Equity and Warrant Liabilities - Equity Offering (Details) $ / shares in Units, $ in Thousands						12 Months Ended
	Aug. 08, 2022 USD ($) shares	Aug. 04, 2022 $ / shares shares	Oct. 12, 2021 USD ($) D $ / shares shares	Oct. 11, 2021 USD ($) shares	Oct. 06, 2021 $ / shares shares	Dec. 31, 2022 USD ($) shares	Dec. 31, 2021 USD ($) $ / shares shares	Sep. 08, 2021 USD ($)
Subsidiary, Sale of Stock [Line Items]
Number of ordinary shares issued | shares		15,451,612
Share Price | $ / shares		$ 0.01
Period of underwriters option					30 days
Exercise price | $ / shares			$ 3.10		$ 0.00001
Proceeds from Issuance of Warrants			$ 8,800
Proceeds from Issuance or Sale of Equity			35,000
Payments of stock issuance cost	$ 300						$ 2,600
Proceeds from issuance of ordinary shares, net of issuance costs			$ 26,200	$ 49,900		$ 23,634	32,414
Warrants and Rights Outstanding, Term			3 years 6 months
Share Issued And Allotted, Price Per Share | $ / shares		$ 1.55
Proceeds from issuance of common stock, gross	$ 23,900
Avista Health Care (Member)
Subsidiary, Sale of Stock [Line Items]
Number of ordinary shares issued | shares	8,000,000
Athyrium (Member)
Subsidiary, Sale of Stock [Line Items]
Number of ordinary shares issued | shares	6,451,612
Brian Markison (Member)
Subsidiary, Sale of Stock [Line Items]
Number of ordinary shares issued | shares	850,000
James Schaub (Member)
Subsidiary, Sale of Stock [Line Items]
Number of ordinary shares issued | shares	150,000
Debt Refinancing 2021 [Member]
Subsidiary, Sale of Stock [Line Items]
Number Of Shares Issued And Allotted To Purchaser | shares			6,148,832
Share Issued And Allotted, Price Per Share | $ / shares			$ 0.01
Debt Refinancing, Shares Issued And Allotted To Purchaser, Amount			$ 15,000
Debt Refinancing, Trading Days | D			60
Fair value of shares issued and allotted to the purchaser.			$ 12,600
Warrants. | Selling, general and administrative expenses
Subsidiary, Sale of Stock [Line Items]
Payments of stock issuance cost							$ 700
Ordinary shares
Subsidiary, Sale of Stock [Line Items]
Number of ordinary shares issued | shares						15,451,612	20,294,994
Payments of stock issuance cost							$ 1,900
Over-Allotment Option [Member]
Subsidiary, Sale of Stock [Line Items]
Number of ordinary shares issued | shares			14,000,000	2,100,000	2,100,000
Number of shares attributable to warrants | shares			16,100,000		2,100,000
Follow On Offering [Member]
Subsidiary, Sale of Stock [Line Items]
Number of ordinary shares issued | shares					14,000,000
Number of shares attributable to warrants | shares					14,000,000
Share Price | $ / shares					$ 2.50
At The Market Equity Offerings 2021 [Member]
Subsidiary, Sale of Stock [Line Items]
Number of ordinary shares issued | shares							146,162
Payments of stock issuance cost							$ 0
Proceeds from issuance of ordinary shares, net of issuance costs						$ 400
Sales agreement, authorized amount								$ 75,000
Weighted-average price | $ / shares							$ 3.13
Proceeds from issuance of common stock, gross							$ 500

Shareholders' Equity and Warr_3

Shareholders' Equity and Warrant Liabilities - Ordinary Share Repurchase Program (Details) - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Sep. 30, 2019
Shareholders' Equity and Warrant Liabilities
Repurchase authorization, number of shares			5,251,892
Shares repurchased, in shares	0	0

Financial Instruments and Fai_3

Financial Instruments and Fair Value Measurements (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Financial Instruments and Fair Value Measurements
Fair value of cash and cash equivalents	$ 44.5	$ 40.4

Financial Instruments and Fai_4

Financial Instruments and Fair Value Measurements - Schedule of valuation techniques and unobservable inputs (Details) $ in Thousands	Dec. 31, 2022 USD ($)	Dec. 31, 2021 $ / shares
Income Approach - DCF
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair Value	(55,500)	(43,800)
Income Approach - DCF | Term (in years)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Inputs	3.8	4.8
Income Approach - DCF | Discount rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Inputs	24.6	17.9
Black-Scholes Merton
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair Value	(1,951)	(3,220)
Black-Scholes Merton | Term (in years)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Inputs	2.3	3.3
Black-Scholes Merton | Equity volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Inputs	60	65

Financial Instruments and Fai_5

Financial Instruments and Fair Value Measurements -Schedule of financial liabilities subject to Level 3 fair value measurements on a recurring basis (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Oct. 31, 2022	Dec. 31, 2021
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Fair Value Adjustment Of Debt
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Liability, Gain (Loss), Statement of Other Comprehensive Income or Comprehensive Income [Extensible Enumeration]	Other Comprehensive Income (Loss), Financial Liability, Fair Value Option, after Tax and Reclassification Adjustment, Attributable to Parent
Long-term debt	$ 55,500,000		$ 43,800,000
Recurring
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Nonfinancial liabilities		$ 0
Senior secured notes
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance, At December 31, 2021	(43,800,000)
Principal issuance of second tranche Senior Secured Notes (Note 8)	(20,000,000)
Cash payments for interest	4,843,000
Fair value adjustments through earnings (inclusive of related accrued interest expense)	2,857,000
Fair value adjustments through accumulated other comprehensive income or loss	(1,700,000)
Balance, At December 31, 2022	2,300,000
Warrants
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance, At December 31, 2021	(3,220,000)
Fair value adjustments through earnings (inclusive of related accrued interest expense)	$ 1,269,000

Subsequent Events - Narratives

Subsequent Events - Narratives (Details) - USD ($) $ / shares in Units, $ in Thousands					1 Months Ended		3 Months Ended	12 Months Ended
	Aug. 08, 2022	Aug. 04, 2022	Mar. 31, 2022	Oct. 01, 2021	Mar. 31, 2023	Feb. 28, 2023	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Mar. 08, 2023	Oct. 12, 2021
Subsequent Event [Line Items]
Number of ordinary shares issued		15,451,612
Share Price		$ 0.01
Share Issued And Allotted, Price Per Share		$ 1.55
Expected additional federal refund claims								$ 1,800
Federal tax refunds for taxes paid in prior periods								(86)	$ (192)
Alora Pharmaceuticals, Llc | Discontinued Operations, Held-for-sale or Disposed of by Sale [Member]
Subsequent Event [Line Items]
Contingent milestone payments earned								$ 5,000
Avista Health Care (Member)
Subsequent Event [Line Items]
Number of ordinary shares issued	8,000,000
Athyrium (Member)
Subsequent Event [Line Items]
Number of ordinary shares issued	6,451,612
Brian Markison (Member)
Subsequent Event [Line Items]
Number of ordinary shares issued	850,000
James Schaub (Member)
Subsequent Event [Line Items]
Number of ordinary shares issued	150,000
Santen Pharmaceutical Co. Ltd. | Exercise of option to expand the territories to include Russia
Subsequent Event [Line Items]
Upfront cash payment			$ 2,000
Developmental and regulatory cash milestone payments			1,000
Santen Pharmaceutical Co. Ltd. | Maximum
Subsequent Event [Line Items]
Developmental and regulatory cash milestone payments			1,000
Santen Pharmaceutical Co. Ltd. | License Agreement
Subsequent Event [Line Items]
Upfront cash payment			$ 15,500
Period of option to expand territories following amendment date			5 years
Senior Secured Notes Under Note Purchase Agreement [Member]
Subsequent Event [Line Items]
Exit fee (as a percent)				2%
Interest rate								12%
Senior Secured Notes Under Note Purchase Agreement, Tranche One [Member]
Subsequent Event [Line Items]
Face amount of debt											$ 55,000
Interest rate	9%
Senior Secured Notes Under Note Purchase Agreement, Tranche Two [Member]
Subsequent Event [Line Items]
Face amount of debt	$ 20,000
Senior Secured Notes Under Note Purchase Agreement, Tranche Three [Member]
Subsequent Event [Line Items]
Face amount of debt	$ 25,000
Prior term loans
Subsequent Event [Line Items]
Face amount of debt											$ 327,500
Subsequent Events
Subsequent Event [Line Items]
Federal tax refunds for taxes paid in prior periods							$ 4,100
Subsequent Events | Alora Pharmaceuticals, Llc
Subsequent Event [Line Items]
Contingent milestone payments earned						$ 5,000
Subsequent Events | Senior Secured Notes Under Note Purchase Agreement [Member]
Subsequent Event [Line Items]
Contingent milestone payments earned					$ 5,000
Subsequent Events | Senior Secured Notes Under Note Purchase Agreement, Tranche Two [Member]
Subsequent Event [Line Items]
Face amount of debt					$ 4,300		$ 4,300
Subsequent Events | Second Amendment to the Note Purchase Agreement
Subsequent Event [Line Items]
Face amount of debt										$ 12,500
Subsequent Events | Second Amendment to the Note Purchase Agreement | Minimum
Subsequent Event [Line Items]
Face amount of debt										$ 15,000